[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 80 of about 80
1. Groff RJ, Nash R, Ahnen DJ: Significance of serrated polyps of the colon. Curr Gastroenterol Rep; 2008 Oct;10(5):490-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of serrated polyps of the colon.
  • The fundamental view that colon adenocarcinomas arise only from conventional adenomas has been challenged by the now recognized hyperplastic polyp-serrated adenoma-adenocarcinoma pathway.
  • This article describes the history of the serrated adenoma (both the traditional serrated adenoma and the sessile serrated adenoma) as well as the histology and endoscopic appearance of these lesions in comparison with hyperplastic polyps and mixed polyps.
  • Management of serrated neoplasia of the colon includes careful colonoscopy, complete removal of colonic polyps, sampling fields of diminutive polyps of the rectosigmoid, and basing surveillance on histology of removed polyps.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1491-501 [17122504.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2711-6 [17227517.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2866-77 [17227527.001]
  • [Cites] Gastrointest Endosc. 2007 May;65(6):757-66 [17466195.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):440-5 [17516746.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):947-68, viii [17996799.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):21-9 [18162766.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):30-5 [18162767.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):25-46, v [18313538.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1027-35 [18319413.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1141-7 [10810411.001]
  • [Cites] Gut. 2000 Jul;47(1):43-9 [10861263.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):827-30 [11221863.001]
  • [Cites] J Pathol. 2001 Mar;193(3):286-94 [11241406.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1296-308 [12094842.001]
  • [Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Pathology. 2002 Dec;34(6):548-55 [12555993.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):705-8 [12598303.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] Mod Pathol. 2003 May;16(5):417-23 [12748247.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):778-96 [12817424.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] Gastrointest Endosc. 1999 Jun;49(6):736-42 [10343219.001]
  • [Cites] Am J Gastroenterol. 2004 Nov;99(11):2242-55 [15555008.001]
  • [Cites] Am J Clin Pathol. 2005 Mar;123(3):349-59 [15716230.001]
  • [Cites] Endoscopy. 2005 Mar;37(3):254-60 [15731942.001]
  • [Cites] Arch Intern Med. 2005 Feb 28;165(4):382-90 [15738366.001]
  • [Cites] Gastrointest Endosc. 2005 Mar;61(3):385-91 [15758908.001]
  • [Cites] Histopathology. 2005 Jul;47(1):32-40 [15982321.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] World J Gastroenterol. 2006 May 7;12(17):2770-2 [16718767.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1400-7 [17101316.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):423-34 [15087661.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] Dis Colon Rectum. 1979 Apr;22(3):152-6 [446245.001]
  • [Cites] Am J Surg Pathol. 1984 Jul;8(7):551-6 [6742315.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4841-7 [3731131.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Pathology. 1992 Oct;24(4):233-42 [1289763.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):423-9 [9247459.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5 [9618505.001]
  • (PMID = 18799125.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA068099-09S1; United States / NCI NIH HHS / CA / R01 CA068099-09S1
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  • [Other-IDs] NLM/ NIHMS210910; NLM/ PMC3437745
  •  go-up   go-down


2. Nouraie M, Hosseinkhah F, Brim H, Zamanifekri B, Smoot DT, Ashktorab H: Clinicopathological features of colon polyps from African-Americans. Dig Dis Sci; 2010 May;55(5):1442-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of colon polyps from African-Americans.
  • The majority of CRC arise from preexisting adenoma.
  • Those pathology reports compatible with the colorectal polyps were carefully reviewed and selected by a GI pathologist.
  • Differences in right-side and left-side polyps for sex, histology, and clinical symptoms were assessed by Chi-2 test.
  • RESULTS: A total number of 5,013 colorectal polyps were diagnosed in this period that include 47% male, with mean age (SD) of 63 (12).
  • Tubular adenoma was the most frequent pathology (73%).
  • The highest frequency of right-sided polyps was observed in the 1990s (56%).
  • Left-sided polyps were younger (p < 0.0001), more hyperplasic (23 vs. 5%; p < 0.0001), and more frequent in female (56 vs. 52%; p = 0.02) compared to right-sided polyps.
  • The frequency of right-sided adenoma significantly increases from 18% in the 1960s to 51% in the period of 2001-2006 (p < 0.0001).
  • CONCLUSION: There was a ratio of 8:1 for neoplastic to hyperplastic polyps in our study, which is more than what has been reported in Caucasians (7:1).
  • Our data shows a shift in polyps from the left side to the right side of the colon in recent years.
  • This data is consistent with the lack of a reduction in the incidence of colon cancer in African-Americans.
  • Screening is thus very important in AA to reduce the incidence of colon cancer.

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):633-9 [15239144.001]
  • [Cites] Arch Intern Med. 2005 Feb 28;165(4):382-90 [15738366.001]
  • [Cites] Cancer. 1973 May;31(5):1260-70 [4705166.001]
  • [Cites] Cancer. 1976 Mar;37(3):1316-21 [816449.001]
  • [Cites] Cancer. 1977 Jan;39(1):274-8 [832242.001]
  • [Cites] Cancer. 1978 Dec;42(6):2839-48 [728878.001]
  • [Cites] Endoscopy. 1979 Feb;11(1):36-42 [428350.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):819-25 [7055790.001]
  • [Cites] Gastrointest Endosc. 1982 Feb;28(1):1-5 [7056447.001]
  • [Cites] Gut. 1982 Oct;23(10):835-42 [7117903.001]
  • [Cites] Scand J Gastroenterol. 1985 Apr;20(3):356-60 [4001845.001]
  • [Cites] Gut. 1985 Oct;26(10):1045-8 [4054702.001]
  • [Cites] Dis Colon Rectum. 1986 Jun;29(6):383-7 [3709316.001]
  • [Cites] Aust N Z J Surg. 1986 Sep;56(9):717-22 [3467704.001]
  • [Cites] Arch Intern Med. 1988 Feb;148(2):473-5 [3341844.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1472-6 [3345499.001]
  • [Cites] Dis Colon Rectum. 1988 Mar;31(3):222-7 [3349879.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):258-60 [3359894.001]
  • [Cites] Adv Cancer Res. 1988;50:1-24 [3287841.001]
  • [Cites] Gastroenterology. 1990 Feb;98(2):371-9 [2403953.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):524-7 [10805835.001]
  • [Cites] World J Gastroenterol. 2005 Aug 14;11(30):4731-4 [16094719.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Oct;20(10):1572-7 [16174076.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Clin Med Res. 2003 Jul;1(3):261-2 [15931318.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Aug;3(8):798-805 [16234009.001]
  • [Cites] Gastrointest Endosc. 2005 Dec;62(6):875-83 [16301030.001]
  • [Cites] Swiss Med Wkly. 2005 Nov 19;135(45-46):679-83 [16453208.001]
  • [Cites] Am J Gastroenterol. 2006 Apr;101(4):823-30 [16494591.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):143-59; quiz 184-5 [16737947.001]
  • [Cites] Cancer Lett. 2006 Aug 18;240(1):143-7 [16288832.001]
  • [Cites] Cancer. 2006 Sep 1;107(5 Suppl):1142-52 [16835912.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Virchows Arch. 2007 Jun;450(6):613-8 [17450379.001]
  • [Cites] J Natl Med Assoc. 2007 Jul;99(7):723-8 [17668638.001]
  • [Cites] J Natl Med Assoc. 2007 Jul;99(7):733-48 [17668639.001]
  • [Cites] Indian J Gastroenterol. 2007 May-Jun;26(3):127-9 [17704579.001]
  • [Cites] Surg Gynecol Obstet. 1947 Jan;84(1):36-49 [20278160.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] Semin Gastrointest Dis. 2000 Oct;11(4):185-93 [11057946.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):222-5 [11500612.001]
  • [Cites] Int J Colorectal Dis. 2001 Aug;16(4):257-61 [11515686.001]
  • [Cites] Surg Endosc. 2002 Mar;16(3):436-40 [11928023.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1035-40 [12195187.001]
  • [Cites] J Assoc Acad Minor Phys. 2002 Jul;13(3):66-8 [12362562.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):422-6 [12588200.001]
  • [Cites] J Clin Epidemiol. 2003 Mar;56(3):209-14 [12725874.001]
  • [Cites] Gut. 2004 Apr;53(4):573-80 [15016754.001]
  • [Cites] Am J Gastroenterol. 1990 Aug;85(8):969-74 [2375325.001]
  • [Cites] Gut. 1992 Nov;33(11):1508-14 [1452076.001]
  • [Cites] N Engl J Med. 1993 Apr 1;328(13):901-6 [8446136.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):159-76 [8467251.001]
  • [Cites] Am J Gastroenterol. 1993 Jun;88(6):825-31 [8503374.001]
  • [Cites] Am J Gastroenterol. 1995 Jan;90(1):24-8 [7801943.001]
  • [Cites] Am J Gastroenterol. 1995 May;90(5):758-60 [7733083.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2101-4 [15657661.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):417-21 [15734967.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1215-22 [15247133.001]
  • (PMID = 20225129.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / #CA102681; United States / NCRR NIH HHS / RR / G12 RR003048-21A1; United States / NCRR NIH HHS / RR / G12 RR003048; United States / NCRR NIH HHS / RR / RR003048-21A1; United States / NCI NIH HHS / CA / R01 CA102681
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS282407; NLM/ PMC3702046
  •  go-up   go-down


3. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res; 2005 Feb 1;11(3):1203-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
  • Colon cancer is the third leading cause of cancer-related death in the United States, affecting approximately 147,000 people each year.
  • Most colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histologic progression sequence that starts from adenomas or hyperplastic polyps/serrated adenomas.
  • Genetic alterations and, more recently, epigenetic alterations have been associated with specific steps in this polyp-adenocarcinoma sequence and likely drive the histologic progression of colon cancer.
  • Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.
  • We have found that methylated MGMT, CDKN2A, and MLH1 occur in 49%, 34%, and 7% of adenomas and in 5%, 10%, and 7% of hyperplastic polyps, respectively, and that they are more common in histologically advanced adenomas.
  • Furthermore, analysis of fecal DNA from persons who have undergone colonoscopic exams revealed methylated CDKN2A, MGMT, and MLH1 in fecal DNA from 31%, 48%, and 0% of individuals with adenomas and from 16%, 27%, and 10% of individuals with no detectable polyps, respectively.
  • These results show that aberrant methylated genes can be detected frequently in sporadic colon polyps and that they can be detected in fecal DNA.
  • Notably, improvements in the specificity and sensitivity of the fecal DNA-based assays will be needed to make them clinically useful diagnostic tests for polyps.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / pathology. Carrier Proteins. Cell Line, Tumor. CpG Islands / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Feces / chemistry. Humans. Hyperplasia. Neoplasm Proteins / genetics. Nuclear Proteins. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709190.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 95103; United States / NCI NIH HHS / CA / U01 CA 094986
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


Advertisement
4. Murff HJ, Shrubsole MJ, Smalley WE, Wu H, Shyr Y, Ness RM, Zheng W: The interaction of age and hormone replacement therapy on colon adenoma risk. Cancer Detect Prev; 2007;31(2):161-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interaction of age and hormone replacement therapy on colon adenoma risk.
  • BACKGROUND: Several studies have identified a possible interaction between age and hormone replacement therapy on colon neoplasm risk.
  • RESULTS: There was a significant interaction between age and hormone replacement therapy use (P=0.03) with current estrogen users who were over 56 years of age having a reduced odds of colon adenoma (OR, 0.40; 95% CI, 0.16-0.98) when compared to never users.
  • CONCLUSIONS: Duration of use is not likely to explain the stronger association of hormone replacement therapy use with colon neoplasm in older women.

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):443-7 [10794491.001]
  • [Cites] Obstet Gynecol. 1999 May;93(5 Pt 2):880-8 [10912438.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):126-30 [11196149.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1799-805 [11734596.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):622-9 [12101109.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):546-52 [15066918.001]
  • [Cites] Lancet. 1970 Sep 12;2(7672):535-7 [4195202.001]
  • [Cites] Cancer Causes Control. 1994 Jul;5(4):359-66 [8080948.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 19;87(14):1067-71 [7616598.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):130-8 [9134236.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):146-58 [9134238.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Apr;7(4):329-33 [9568789.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Aug;7(8):653-9 [9718216.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):212-7 [10211498.001]
  • [Cites] Am J Med. 1999 May;106(5):574-82 [10335731.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1219-23 [15894675.001]
  • [Cites] Cancer Causes Control. 2005 Oct;16(8):965-73 [16132805.001]
  • (PMID = 17433566.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / K07 CA114029; United States / NCI NIH HHS / CA / R01 CA097386-01; United States / NCI NIH HHS / CA / K07 CA114029-01A2; United States / NCI NIH HHS / CA / R01 CA097386; United States / NCI NIH HHS / CA / P50 CA095103-01; United States / NCI NIH HHS / CA / CA95103; United States / NCI NIH HHS / CA / CA097386-01; United States / NCI NIH HHS / CA / R01 CA97386
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS24075; NLM/ PMC1949417
  •  go-up   go-down


5. Jung WT, Li MS, Goel A, Boland CR: JC virus T-antigen expression in sporadic adenomatous polyps of the colon. Cancer; 2008 Mar 1;112(5):1028-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JC virus T-antigen expression in sporadic adenomatous polyps of the colon.
  • The hypothesis that JCV DNA sequences and T-antigen (T-Ag) expression may be present in adenomatous polyps of the colon was tested.
  • METHODS: DNA was extracted from 74 paraffin-embedded adenomatous polyps.
  • For microsatellite instability analysis, 5 mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24, and NR-27) were coamplified in a pentaplex PCR and analyzed for deletion mutations.
  • RESULTS: JCV T-Ag sequences were found in 82% (61 of 74) of adenomas, and T-Ag protein was expressed in 16% (12 of 74) of these polyps.
  • The T-Ag staining was localized exclusively in the nuclei of adenoma cells, but never in the cytoplasm or the adjacent nonneoplastic cells.
  • The prevalence of MSI-H and non-MSI-H (MSI-L/MSS) in adenomatous polyps was 9.5% (7 of 74) and 90.5% (67 of 74), respectively.
  • Among the 61 adenomas that harbored JCV sequences, 8% (5 of 61) were MSI-H, and similarly among 12 adenomatous polyps expressing T-Ag protein 8% (1 of 12) of the adenomatous polyps were MSI-H.
  • CONCLUSIONS: JCV T-Ag DNA sequences are frequently present in adenomatous polyps of the colon, and T-Ag is expressed specifically in the nuclei of these premalignant lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8332-40 [16322293.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(17):6233-43 [10938100.001]
  • [Cites] Virology. 2000 Aug 15;274(1):165-78 [10936097.001]
  • [Cites] Int J Colorectal Dis. 2000 Aug;15(4):189-96 [11008717.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1228-35 [11054380.001]
  • [Cites] J Virol. 2001 Feb;75(4):1996-2001 [11160700.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4287-93 [11358858.001]
  • [Cites] Oncogene. 2001 Aug 9;20(35):4864-70 [11521197.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Gut. 2002 Mar;50(3):382-6 [11839719.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):267-73 [11854388.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7093-101 [12460931.001]
  • [Cites] J Neurovirol. 2002 Dec;8 Suppl 2:138-47 [12491166.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1499-504 [12771419.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5181-91 [12910255.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):42-8 [14699485.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Microbiol Immunol. 1982;26(11):1057-64 [6300615.001]
  • [Cites] J Virol. 1984 Aug;51(2):458-69 [6086957.001]
  • [Cites] J Virol. 1989 Feb;63(2):863-72 [2536108.001]
  • [Cites] J Virol. 1990 Mar;64(3):1353-6 [2154613.001]
  • [Cites] J Virol. 1992 Jul;66(7):3979-85 [1318392.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1645-8 [8137274.001]
  • [Cites] Int J Mol Med. 1998 Apr;1(4):647-55 [9852278.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7484-9 [10377441.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Dec;20(12):1920-6 [16336454.001]
  • [Cites] Gut. 2006 May;55(5):695-702 [16354798.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):1950-61 [16762618.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):481-8 [16795066.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Nov;63(11):1124-30 [15581180.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):516-27 [15630684.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):86-91 [15690663.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1143-9 [15842591.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):1079-85 [15868949.001]
  • [Cites] Gut. 2005 Sep;54(9):1321-31 [16099799.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):723-30 [16021515.001]
  • [Cites] Gut. 2000 Jul;47(1):37-42 [10861262.001]
  • (PMID = 18205186.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098572-05; United States / NCI NIH HHS / CA / R01 CA098572; United States / NCI NIH HHS / CA / R01 CA 98572; United States / NCI NIH HHS / CA / R01 CA098572-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS187525; NLM/ PMC2855201
  •  go-up   go-down


6. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S: Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer; 2008 Jan 29;8:33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma.
  • METHODS: By immunohistochemistry, we assessed COX-2 expression in 24 hyperplastic polyps, 7 sessile serrated polyp/adenomas (SSA), 5 mixed polyps with SSA and adenoma, 27 traditional serrated adenomas, 515 non-serrated adenomas (tubular adenoma, tubulovillous adenoma and villous adenoma), 33 adenomas with intramucosal carcinomas, 96 adenocarcinomas with serration (corkscrew gland) and 111 adenocarcinomas without serration.
  • RESULTS: Strong (2+) COX-2 overexpression was more common in non-serrated adenomas (28% = 143/515) than in hyperplastic polyps (4.2% = 1/24, p = 0.008) and serrated polyps (7 SSAs and 5 mixed polyps) (0% = 0/12, p = 0.04).
  • Furthermore, any (1+/2+) COX-2 overexpression was more frequent in non-serrated adenomas (60% = 307/515) than in hyperplastic polyps (13% = 3/24, p < 0.0001) and serrated polyps (SSAs and mixed polyps) (25% = 3/12, p = 0.03).
  • Tumor location was not significantly correlated with COX-2 overexpression, although there was a trend towards higher frequencies of COX-2 overexpression in distal tumors (than proximal tumors) among hyperplastic polyps, SSAs, mixed polyps, traditional serrated adenomas and adenocarcinomas.
  • CONCLUSION: COX-2 overexpression is infrequent in hyperplastic polyp, SSA and mixed polyp with SSA and adenoma, compared to non-serrated and serrated adenoma.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 1998 Jul;28(7):421-6 [9739782.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4044-8 [10945606.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):350-8 [10419916.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8465-71 [15623626.001]
  • [Cites] Dig Dis Sci. 2004 Nov-Dec;49(11-12):1906-11 [15628724.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):254-66 [15637389.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):130-8 [15654792.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):429-36 [15767794.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2840-55 [15837998.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):388-96 [15864280.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4754-60 [16000571.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6738-44 [16166455.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Oncology. 2005;69 Suppl 1:33-7 [16210875.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):59-68 [16118624.001]
  • [Cites] BMC Cancer. 2006;6:9 [16409625.001]
  • [Cites] Histopathology. 2006 Mar;48(4):431-7 [16487365.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):458-64 [16820091.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] BMC Cancer. 2006;6:181 [16831226.001]
  • [Cites] J Pathol. 2006 Oct;210(2):137-40 [16917802.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1319-23 [11584208.001]
  • [Cites] Int J Colorectal Dis. 2002 May;17(3):144-9 [12049307.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):705-8 [12598303.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):786-92 [12794581.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Aug;129(8):449-55 [12884030.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):267-71 [14734479.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):213-9 [14745394.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Jun;16(6):619-25 [15167166.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Ann Intern Med. 1994 Aug 15;121(4):241-6 [8037405.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):253-63 [8740738.001]
  • [Cites] Crit Rev Oncog. 2006 Jul;12(1-2):27-39 [17078205.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]
  • [Cites] N Engl J Med. 2007 May 24;356(21):2195-8 [17522404.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5473-7 [9850081.001]
  • (PMID = 18230181.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / K07 CA122826; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / P01 CA55075; United States / NCI NIH HHS / CA / P50 CA127003
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ PMC2257954
  •  go-up   go-down


7. Rubio CA, Jónasson JG, Nesi G, Mazur J, Olafsdóttir E: The size of colon polyps revisited: intra- and inter-observer variations. Anticancer Res; 2010 Jun;30(6):2419-23
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The size of colon polyps revisited: intra- and inter-observer variations.
  • BACKGROUND: It has been postulated that the occurrence of invasive carcinoma in a colon adenoma can be predicted by estimating the size of the resected polyp.
  • In this work, the size of a large cohort of endoscopically-resected colon polyps was assessed with a novel method.
  • PATIENTS AND METHODS: Three pathologists measured photocopies of 148 resected polyps (adenomas at histology) in two independent trials.
  • CONCLUSION: Present and previous investigations indicate that the lack of reproducibility makes the use of size limits in predicting cancer risk in polyps removed at colonoscopy unreliable.
  • [MeSH-major] Colonic Polyps / pathology
  • [MeSH-minor] Adenoma / pathology. Carcinoma / pathology. Colonic Neoplasms / pathology. Humans. Observer Variation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651402.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


8. Messick CA, Church J, Casey G, Kalady MF: Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated polyps. Dis Colon Rectum; 2009 Sep;52(9):1535-41
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated polyps.
  • PURPOSE: Colorectal cancers arise via cumulative genetic and molecular changes that cause mucosal instability, premalignant polyps, and malignant transformation.
  • Distinct neoplastic pathways characterized by chromosomal instability, genetic mutation, and epigenetic methylation have been described, but their associated precursor polyps have not.
  • This study analyzes characteristics of precursor polyps occurring within different molecular subtypes of sporadic colorectal cancer.
  • The proportion of patients with synchronous polyps and polyp number, size, and location were similar.
  • Microsatellite stable tumors, regardless of methylator status, had a greater proportion of adenomas than microsatellite unstable tumors, which had an increased proportion of serrated polyps (P = 0.029).
  • CONCLUSIONS: Patients with microsatellite unstable colorectal cancers demonstrate an increased serrated polyp-to-adenoma ratio compared with microsatellite stable cancers regardless of methylator status.
  • An increased proportion of serrated polyps to adenomas discovered in patients on colonoscopy should arouse suspicion that cancers arising in these patients are probably microsatellite unstable.
  • [MeSH-major] Adenoma / genetics. Adenoma / pathology. Colonic Polyps / genetics. Colonic Polyps / pathology. Colorectal Neoplasms / genetics. Microsatellite Instability

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19690479.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Torlakovic E, Snover DC: Sessile serrated adenoma: a brief history and current status. Crit Rev Oncog; 2006 Jul;12(1-2):27-39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sessile serrated adenoma: a brief history and current status.
  • Sessile serrated adenoma (SSA) is a polyp of the large intestine, which was first described in 1996.
  • It presents as a solitary lesion or in a setting of a polyposis previously coined as "serrated adenomatous polyposis."
  • The importance of correct recognition of this lesion and distinction from other serrated polyps of the colon is in that the newly described "serrated pathway" of colorectal carcinogenesis seems to apply mostly to SSA and not to other serrated polyps of the colon.
  • This review describes the history of morphologic discovery of SSA and reports on current status of this lesion.
  • [MeSH-major] Adenomatous Polyps / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17078205.001).
  • [ISSN] 0893-9675
  • [Journal-full-title] Critical reviews in oncogenesis
  • [ISO-abbreviation] Crit Rev Oncog
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


10. Nosho K, Yamamoto H, Takamaru H, Hamamoto Y, Goto A, Yoshida Y, Arimura Y, Endo T, Hirata K, Imai K: A case of colorectal carcinoma in adenoma analyzed by a cDNA array. Int J Colorectal Dis; 2005 May;20(3):287-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of colorectal carcinoma in adenoma analyzed by a cDNA array.
  • Colonoscopy showed a Is-type tumor of 45 mm in diameter in the cecum and three Is-type tumors in the ascending colon.
  • Microscopically, the large tumor consisted of a well-differentiated adenocarcinoma with a tubulovillous adenoma (TVA) component (carcinoma in adenoma).
  • Some carcinoma (CA) cells had invaded the submucosal layer, but the lymph nodes were negative for malignancy.
  • The other three polyps were diagnosed as TVAs.
  • Because her family history fulfilled the Amsterdam criteria II for hereditary non-polyposis colorectal cancer (HNPCC), genetic analysis was performed.
  • K-ras mutation was detected in both CA and TVA lesions of the carcinoma in adenoma.
  • To clarify relevant alterations of gene expression associated with adenoma-carcinoma progression, the gene expression profiles of these tumor tissues were analyzed by a cDNA array.
  • RESULTS: Although the gene expression profiles were similar, insulin-like growth factor-II (IGF-II) was expressed most differentially in CA and TVA tissues.
  • The results were further substantiated by comparison of the gene expression profiles of CA and TVA lesions of the carcinoma in adenoma.
  • CONCLUSION: The results suggest that overexpression of IGF-II played an important role in the progression of adenoma to carcinoma in this patient.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma, Villous / genetics. Colorectal Neoplasms / genetics. DNA, Complementary / analysis. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15490195.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / RNA, Messenger; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


11. Terdiman JP, Johnson LK, Kim YS, Sleisenger MH, Gum JR, Hayes A, Weinberg VK, McQuaid KR: Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. Dig Dis Sci; 2009 Nov;54(11):2488-96
Hazardous Substances Data Bank. MESALAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study.
  • AIM: To investigate chemoprevention of colonic polyps with balsalazide, a 5-aminosalicylate prodrug.
  • METHODS: In this randomized, double-blind, placebo-controlled study, adults diagnosed with small polyps in the rectosigmoid colon were treated with either balsalazide 3 g/d or placebo for 6 months.
  • Follow-up lower endoscopy was performed, and all polyps were measured and analyzed histologically.
  • Balsalazide 3 g/d (n = 38) did not significantly reduce the mean size of the largest colonic polyp or the number of polyps compared with placebo (n = 37).
  • Although not significant, post-hoc analysis revealed that total adenoma burden per subject, calculated as the sum of the volumes of all adenomas in mm3, increased by 55% in the balsalazide group compared with 95% in the placebo group.
  • CONCLUSIONS: Although balsalazide did not have significant chemopreventive effects on established colonic polyps, these results can aid in designing future prospective studies.
  • [MeSH-major] Colonic Polyps / prevention & control. Gastrointestinal Agents / therapeutic use. Mesalamine / therapeutic use. Phenylhydrazines / therapeutic use
  • [MeSH-minor] Adenoma / pathology. Adenoma / prevention & control. Aged. Apoptosis / drug effects. Colon, Sigmoid / pathology. Colonic Neoplasms / pathology. Colonic Neoplasms / prevention & control. Double-Blind Method. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aliment Pharmacol Ther. 1999 Nov;13(11):1397-402 [10571594.001]
  • [Cites] Inflamm Bowel Dis. 2008 Feb;14(2):265-74 [17932965.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):173-9 [10853036.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Med Clin North Am. 2000 Sep;84(5):1163-82, viii [11026923.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3053-63 [11095318.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1398-407 [12094857.001]
  • [Cites] Inflamm Bowel Dis. 2002 Sep;8(5):356-61 [12479651.001]
  • [Cites] JAMA. 2003 Mar 12;289(10):1288-96 [12633191.001]
  • [Cites] Am J Gastroenterol. 2003 Aug;98(8):1682-7 [12907319.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:15-21 [12950416.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2784-8 [14687833.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Feb 15;19(4):435-42 [14871283.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1423-47 [15131803.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Gastroenterol Clin North Am. 1996 Dec;25(4):821-58 [8960895.001]
  • [Cites] Gastroenterology. 1998 Jan;114(1):15-22 [9428213.001]
  • [Cites] Aliment Pharmacol Ther. 1998 Dec;12(12):1207-16 [9882028.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1205-15 [15824083.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3993-7 [15899787.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1345-53 [15929768.001]
  • [Cites] Gut. 2005 Nov;54(11):1573-8 [15994215.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):143-59; quiz 184-5 [16737947.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):221-35 [17241873.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):365-75 [17339622.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):376-89 [17339623.001]
  • [Cites] Inflamm Bowel Dis. 2007 Apr;13(4):367-71 [17206695.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1869-81 [18054559.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(6):1031-48 [18070702.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Feb;14(2):145-53 [10651654.001]
  • (PMID = 19757048.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrointestinal Agents; 0 / Phenylhydrazines; 4Q81I59GXC / Mesalamine; P80AL8J7ZP / balsalazide
  • [Other-IDs] NLM/ PMC2762046
  •  go-up   go-down


12. Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, Rao SM, Witt RC, Ternent CA, Talamonti MS, Bell RH, Adrian TA: Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res; 2008 Oct 15;14(20):6525-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model.
  • The purpose of this study was to evaluate the expression of 5-LOX in colonic polyps and cancer and the effect of 5-LOX inhibition on colon cancer cell proliferation.
  • EXPERIMENTAL DESIGN: Colonic polyps, cancer, and normal mucosa were evaluated for 5-LOX expression by immunohistochemistry.
  • Reverse transcription-PCR was used to establish 5-LOX expression in colon cancer cells.
  • A heterotopic xenograft model in athymic mice using HT29 and LoVo human colon cancer cells was used to evaluate the effect of the 5-LOX inhibitor zileuton on tumor growth.
  • RESULTS: 5-LOX is overexpressed in adenomatous polyps and cancer compared with that of normal colonic mucosa.
  • LOX inhibition and 5-LOX inhibition decreased DNA synthesis in a concentration- and time-dependent manner in the Lovo cell line (P < 0.05).
  • Inhibition of 5-LOX in an in vivo colon cancer xenograft model inhibited tumor growth compared with that of controls (P < 0.05).
  • CONCLUSIONS: This study showed that 5-LOX is up-regulated in adenomatous colon polyps and cancer compared with normal colonic mucosa.
  • The blockade of 5-LOX inhibits colon cancer cell proliferation both in vitro and in vivo and may prove a beneficial chemopreventive therapy in colon cancer.
  • [MeSH-major] Arachidonate 5-Lipoxygenase / metabolism. Colonic Neoplasms / enzymology. Colonic Polyps / enzymology. Disease Models, Animal. Lipoxygenase Inhibitors / pharmacology
  • [MeSH-minor] Adenoma / drug therapy. Adenoma / enzymology. Adenoma / pathology. Animals. Apoptosis / drug effects. Cell Proliferation / drug effects. Female. Humans. Immunoenzyme Techniques. In Vitro Techniques. Masoprocol / therapeutic use. Mice. Mice, Inbred BALB C. Mice, Nude. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Thymidine / metabolism. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18927292.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipoxygenase Inhibitors; 0 / RNA, Messenger; 7BO8G1BYQU / Masoprocol; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; VC2W18DGKR / Thymidine
  •  go-up   go-down


13. Wallace K, Grau MV, Ahnen D, Snover DC, Robertson DJ, Mahnke D, Gui J, Barry EL, Summers RW, McKeown-Eyssen G, Haile RW, Baron JA: The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomarkers Prev; 2009 Aug;18(8):2310-7
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum.
  • Some serrated polyps of the colorectum are likely preinvasive lesions, evolving through a newly recognized serrated pathway to colorectal cancer.
  • To assess possible risk and protective factors for serrated polyps and particularly to explore differences in risk factors between polyps in the right and left colorectum, we pooled data from three large multicenter chemoprevention trials.
  • A serrated polyp was defined broadly as any serrated lesion (hyperplastic, sessile serrated adenoma, "traditional" serrated adenoma, mixed adenoma) diagnosed during each trial's main treatment period of approximately 3 to 4 years.
  • Using generalized linear regression, we computed risk ratios and 95% confidence intervals as measures of the association between risk for serrated polyps and demographic, lifestyle, and dietary variables.
  • In the left colorectum, obesity, cigarette smoking, dietary fat, total energy intake, and red meat intake were associated with an increased risk for serrated polyps.
  • In the right colon, aspirin treatment was associated with a reduced risk and family history of polyps and folate treatment were associated with an increased risk for serrated polyps.
  • Our results suggest that several common lifestyle and dietary variables are associated with risk for serrated polyps, and some of these may differ for the right and left colorectum.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1831-6 [11078760.001]
  • [Cites] Am J Epidemiol. 2009 Mar 15;169(6):657-66 [19147743.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Pathology. 2002 Dec;34(6):548-55 [12555993.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] JAMA. 2003 Dec 10;290(22):2959-67 [14665657.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):423-34 [15087661.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1089-93 [15452166.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] Am J Epidemiol. 1989 Feb;129(2):445-9 [2912053.001]
  • [Cites] Am J Epidemiol. 1989 Jul;130(1):173-87 [2741904.001]
  • [Cites] J Clin Epidemiol. 1990;43(12):1327-35 [2254769.001]
  • [Cites] N Engl J Med. 1994 Jul 21;331(3):141-7 [8008027.001]
  • [Cites] Epidemiol Rev. 1994;16(2):273-97 [7713180.001]
  • [Cites] Cancer Causes Control. 1995 Jan;6(1):45-56 [7718735.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):423-9 [9247459.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):69-75 [9950242.001]
  • [Cites] J Clin Pathol. 1999 Jan;52(1):5-9 [10343605.001]
  • [Cites] J Surg Oncol. 2004 Dec 15;88(4):261-6 [15565587.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):914-9 [15856472.001]
  • [Cites] Cancer Causes Control. 2005 Nov;16(9):1021-33 [16184467.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Jan;22(1):48-53 [16319676.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):897-901 [16702367.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1778-84 [17035382.001]
  • [Cites] Crit Rev Oncog. 2006 Jul;12(1-2):27-39 [17078205.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1491-501 [17122504.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 6;98(23):1731-8 [17148775.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):115-26 [17021745.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Histopathology. 2007 Jan;50(1):131-50 [17204027.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):938-45 [17509991.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Virchows Arch. 2007 Jun;450(6):613-8 [17450379.001]
  • [Cites] J Natl Med Assoc. 2007 Jul;99(7):733-48 [17668639.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):21-9 [18162766.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):30-5 [18162767.001]
  • [Cites] Carcinogenesis. 2008 Apr;29(4):673-80 [17942460.001]
  • [Cites] Am J Epidemiol. 2008 May 1;167(9):1050-8 [18304959.001]
  • [Cites] Mol Cancer. 2008;7:68 [18718023.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • (PMID = 19661090.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA037287; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / CA059005; United States / NCI NIH HHS / CA / CA046927; United States / NCI NIH HHS / CA / U01 CA046927; United States / NCI NIH HHS / CA / R01 CA059005
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antioxidants; R16CO5Y76E / Aspirin; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS471973; NLM/ PMC3669681
  •  go-up   go-down


14. Wernli KJ, Newcomb PA, Wang Y, Makar KW, Shadman M, Chia VM, Burnett-Hartman A, Wurscher MA, Zheng Y, Mandelson MT: Body size, IGF and growth hormone polymorphisms, and colorectal adenomas and hyperplastic polyps. Growth Horm IGF Res; 2010 Aug;20(4):305-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body size, IGF and growth hormone polymorphisms, and colorectal adenomas and hyperplastic polyps.
  • OBJECTIVE: We examined the risk of colorectal polyps in relation to body size factors and candidate polymorphisms in selected genes of insulin-like growth factor (IGF1) (rs5742612), IGF1 receptor (IGF1R) (rs2229765), IGF binding protein 3 (IGFBP3) (rs2854746) and growth hormone (GH1) (rs2665802).
  • DESIGN: Cases with colorectal adenomas (n=519), hyperplastic polyps (n=691), or both lesions (n=227), and controls (n=772), aged 20-74 years, were recruited from patients who underwent colonoscopy between December 2004 and September 2007 at a large integrated-health plan in Washington state.
  • Subjects participated in a 45-minute telephone interview to ascertain body size and physical activity, and provided a buccal DNA sample for genetic analysis.
  • RESULTS: Compared to those of normal weight, higher body mass index (BMI) was associated with elevated risk of colorectal adenomas (OR=1.65, 95% CI 1.22-2.25 BMI>or=30 kg/m(2), p-trend=0.002) and both lesions (OR=2.15, 95% CI 1.43-3.22 BMI>or=30 kg/m(2), p-trend=0.003), but there was no relationship with hyperplastic polyps.
  • Obesity at age 18 and a weight gain of >or=21 kg since age 18 were also significantly associated with an increased risk of colorectal adenomas and both lesions, but not hyperplastic polyps.
  • There was a reduced risk of colorectal adenomas (OR=0.63, 95% CI 0.42-0.94) and hyperplastic polyps (OR=0.7, 95% CI 0.5-0.9) associated with the homozygous variant genotype for GH1.
  • CONCLUSIONS: There is an increased risk of colorectal adenomas and presence of both adenomas and hyperplastic polyps in relation to increasing body size.
  • Some genetic variation in GH1 might contribute to a reduced risk of colorectal adenomas and hyperplastic polyps.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Growth Hormone Research Society. Published by Elsevier Ltd. All rights reserved.
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1307-13 [11535705.001]
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):2238-46 [11467659.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):454-60 [11904318.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):972-80 [12096082.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3299-304 [12843179.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):712-25 [14710350.001]
  • [Cites] Lancet. 2004 Apr 24;363(9418):1346-53 [15110491.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):983-92 [15128611.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1206-14 [15247132.001]
  • [Cites] J Natl Cancer Inst. 1991 Mar 6;83(5):359-61 [1995919.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):670-80 [9554606.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Aug;7(8):719-24 [9718225.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1154-60 [15842593.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1204-11 [15894673.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2082-6 [16172213.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):526-31 [17372248.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Aug;5(8):982-90 [17553754.001]
  • [Cites] Hum Pathol. 2007 Nov;38(11):1590-602 [17651787.001]
  • [Cites] J Surg Res. 2007 Dec;143(2):294-9 [17764692.001]
  • [Cites] Cancer Detect Prev. 2007;31(5):408-16 [18031946.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2533-47 [18086756.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R42 [18471292.001]
  • [Cites] Cancer Causes Control. 2010 Jan;21(1):91-7 [19784788.001]
  • [Cites] J Hum Genet. 2010 Mar;55(3):163-6 [20168335.001]
  • [Cites] Proc Nutr Soc. 2001 Feb;60(1):91-106 [11310428.001]
  • [Cites] Nutr Cancer. 2001;39(1):50-7 [11588902.001]
  • (PMID = 20580999.001).
  • [ISSN] 1532-2238
  • [Journal-full-title] Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • [ISO-abbreviation] Growth Horm. IGF Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA097325-06; United States / NCI NIH HHS / CA / R25 CA94880; United States / NCI NIH HHS / CA / R25 CA094880; United States / NCI NIH HHS / CA / U24 CA074794; United States / NCI NIH HHS / CA / T32 CA09168-32; United States / NCI NIH HHS / CA / U01 CA074794; United States / NCI NIH HHS / CA / T32 CA009168; United States / NCI NIH HHS / CA / R01 CA 097325; United States / NCI NIH HHS / CA / K05 CA152715; United States / NCI NIH HHS / CA / CA097325-06; United States / NCI NIH HHS / CA / R01 CA097325
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ NIHMS202379; NLM/ PMC2918710
  •  go-up   go-down


15. Jacobs ET, Martínez ME, Alberts DS, Jiang R, Lance P, Lowe KA, Thompson PA: Association between body size and colorectal adenoma recurrence. Clin Gastroenterol Hepatol; 2007 Aug;5(8):982-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between body size and colorectal adenoma recurrence.
  • BACKGROUND & AIMS: Obesity has been associated with increased risk for colorectal adenoma, although its role as a risk factor after polypectomy for recurrence is unclear.
  • Therefore, we sought to evaluate the effect of anthropometric measures of obesity on adenoma after polypectomy.
  • METHODS: Subjects with baseline adenomas (n = 2465) and follow-up colonoscopy data were drawn from 2 randomized trials designed to prevent adenoma recurrence.
  • RESULTS: Over a mean follow-up period of 3.1 years presence of a body mass index (BMI) > or = 30 kg/m2 was associated with a nonsignificant 17% increase in the odds for any adenoma recurrence among all subjects (odds ratio [OR], 1.17; 95% confidence interval [CI], 0.92-1.48).
  • Analyses of the effects of obesity on more clinically significant lesions demonstrated that high BMI was a slightly stronger risk factor for advanced adenoma recurrences in men (OR, 1.62; 95% CI, 1.04-2.53) when compared with non-advanced lesions (OR, 1.26; 95% CI, 0.91-1.75).
  • In addition, we observed an association for obesity and odds of adenoma recurrence among participants reporting a family history of colorectal cancer (OR, 2.25; 95% CI, 1.32-3.84) but not for those without (OR, 1.00; 95% CI, 0.77 to 1.31; P(int) = P = .008).

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1149-55 [10770979.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1350-5 [1406836.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 May;278(5):E941-8 [10780952.001]
  • [Cites] Horm Res. 2005;64 Suppl 2:37-40 [16286769.001]
  • [Cites] Gut. 2006 Jan;55(1):62-7 [15972299.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1496-500 [16187280.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] BMC Gastroenterol. 2006;6:5 [16412216.001]
  • [Cites] Int J Obes (Lond). 2006 Mar;30(3):475-83 [16261188.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):143-59; quiz 184-5 [16737947.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):920-31 [16818856.001]
  • [Cites] Br J Cancer. 1993 Jan;67(1):177-84 [8381298.001]
  • [Cites] Cancer Causes Control. 1994 Jan;5(1):38-52 [8123778.001]
  • [Cites] Gynecol Endocrinol. 1993 Dec;7(4):251-8 [8147234.001]
  • [Cites] Eur J Cancer. 1994;30A(3):344-50 [8204357.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):327-34 [7847643.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Apr;5(4):313-5 [8722224.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):253-63 [8740738.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):948-55 [9214674.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):670-80 [9554606.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):161-5 [9754646.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):45-51 [9950239.001]
  • [Cites] Annu Rev Med. 2005;56:45-62 [15660501.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):846-53 [15928305.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2082-6 [16172213.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):137-44 [8419236.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):805-11 [10543250.001]
  • [Cites] Am J Epidemiol. 2000 Nov 1;152(9):847-54 [11085396.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1077-83 [11266371.001]
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):2238-46 [11467659.001]
  • [Cites] Nutr Cancer. 2001;39(1):50-7 [11588902.001]
  • [Cites] Eur J Nutr. 2002 Feb;41(1):35-43 [11990006.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):622-9 [12101109.001]
  • [Cites] Gut. 2002 Aug;51(2):147 [12117867.001]
  • [Cites] Gut. 2002 Aug;51(2):191-4 [12117878.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):75-84 [12708728.001]
  • [Cites] Diabetologia. 2003 Apr;46(4):459-69 [12687327.001]
  • [Cites] Trends Pharmacol Sci. 2003 Sep;24(9):479-85 [12967773.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):879-87 [14682445.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):694-704 [14710348.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):323-33 [14991494.001]
  • [Cites] Int J Obes Relat Metab Disord. 2004 Apr;28(4):559-67 [14770200.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):553-9 [15066919.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):687-93 [15089903.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):983-92 [15128611.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):921-5 [15199111.001]
  • [Cites] JAMA. 2004 Jun 16;291(23):2847-50 [15199035.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):581-9 [15280637.001]
  • [Cites] J Chronic Dis. 1979;32(8):563-76 [468958.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):307-17 [3856044.001]
  • [Cites] Am J Clin Nutr. 1988 Feb;47(2):312-7 [3341261.001]
  • [Cites] Am J Epidemiol. 1988 Sep;128(3):490-503 [2843038.001]
  • [Cites] Am J Epidemiol. 1989 Jan;129(1):125-37 [2910056.001]
  • [Cites] J Natl Cancer Inst. 1991 Mar 6;83(5):359-61 [1995919.001]
  • [Cites] Cancer Causes Control. 1992 Jul;3(4):349-54 [1617122.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 2;84(17):1326-31 [1495102.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • (PMID = 17553754.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA106269; United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / 1K07CA10629-01A1; United States / NCI NIH HHS / CA / CA95060; United States / NCI NIH HHS / CA / CA-41108; United States / NCI NIH HHS / CA / P01 CA041108; United States / NCI NIH HHS / CA / P50 CA095060; United States / NCI NIH HHS / CA / CA-23074; United States / NCI NIH HHS / CA / K07 CA106269-01A1; United States / NCI NIH HHS / CA / CA106269-01A1; United States / NCI NIH HHS / CA / CA-77145
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS29366; NLM/ PMC2729188
  •  go-up   go-down


16. Shaukat A, Parekh M, Lipscomb J, Ladabaum U: Can calcium chemoprevention of adenoma recurrence substitute or serve as an adjunct for colonoscopic surveillance? Int J Technol Assess Health Care; 2009 Apr;25(2):222-31
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can calcium chemoprevention of adenoma recurrence substitute or serve as an adjunct for colonoscopic surveillance?
  • METHODS: We constructed a Markov model of post-polypectomy adenoma recurrence and colorectal cancer (CRC) development, calibrated to data from prospective chemoprevention trials of fiber, calcium, antioxidants, and aspirin.
  • (iii) surveillance colonoscopy from age 50-80 every 5 years, or 3 years for large adenoma;.
  • [MeSH-major] Adenoma / prevention & control. Calcium / economics. Colonic Polyps / prevention & control. Colonoscopy. Colorectal Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2000 Oct 18;284(15):1954-61 [11035892.001]
  • [Cites] Ann Intern Med. 2000 Oct 17;133(8):573-84 [11033584.001]
  • [Cites] Semin Gastrointest Dis. 2000 Oct;11(4):176-84 [11057945.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3053-63 [11095318.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1077-83 [11266371.001]
  • [Cites] Aliment Pharmacol Ther. 2001 May;15(5):631-8 [11328256.001]
  • [Cites] J Am Coll Nutr. 2001 Jun;20(3):239-46 [11444420.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Ann Intern Med. 2001 Nov 6;135(9):769-81 [11694102.001]
  • [Cites] Am J Med. 2001 Dec 1;111(8):593-601 [11755501.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):78-84 [11781283.001]
  • [Cites] Curr Pharm Des. 2002;8(12):1035-62 [11945150.001]
  • [Cites] J Am Diet Assoc. 2002 Nov;102(11):1669-71 [12449293.001]
  • [Cites] Nutr Cancer. 2002;43(1):39-46 [12467133.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Dec;31(4):925-43 [12489270.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):905-41 [12507200.001]
  • [Cites] J Rheumatol. 2003 Jan;30(1):132-8 [12508402.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S65-70 [12570337.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Am J Med. 2003 May;114(7):546-54 [12753878.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1237-46 [12818263.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):601-14 [12894248.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):323-33 [14991494.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1270-9 [15131787.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):554-63 [15224279.001]
  • [Cites] Clin Radiol. 1984 Nov;35(6):425-31 [6499378.001]
  • [Cites] Dis Colon Rectum. 1986 Jun;29(6):383-7 [3709316.001]
  • [Cites] Gastroenterology. 1987 Mar;92(3):682-92 [3102307.001]
  • [Cites] Ann Intern Med. 1990 Sep 1;113(5):373-84 [2200321.001]
  • [Cites] N Engl J Med. 1993 Apr 1;328(13):901-6 [8446136.001]
  • [Cites] Mutat Res. 1993 Nov;290(1):87-95 [7694103.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] N Engl J Med. 1994 Jul 21;331(3):141-7 [8008027.001]
  • [Cites] Nutr Rev. 1994 Jul;52(7):221-32 [8090373.001]
  • [Cites] Gastroenterology. 1995 Feb;108(2):402-8 [7835580.001]
  • [Cites] J Natl Cancer Inst. 1995 Mar 15;87(6):417-26 [7861461.001]
  • [Cites] Semin Gastrointest Dis. 1996 Apr;7(2):105-16 [8705258.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):594-642 [9024315.001]
  • [Cites] Health Care Financ Rev. 1997 Summer;18(4):51-76 [10175613.001]
  • [Cites] Crit Rev Oncog. 1996;7(5-6):293-342 [9467664.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):163-8 [9488592.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):221-5 [9521437.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Pharmacoeconomics. 1998 Nov;14(5):559-73 [10344918.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):390-4 [15667497.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):433-7 [10744815.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1149-55 [10770979.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • [Cites] Semin Gastrointest Dis. 2000 Jul;11(3):142-6 [10950460.001]
  • [Cites] Int J Technol Assess Health Care. 2000 Summer;16(3):799-810 [11028135.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2353-8 [16214916.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1151-62 [16230069.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):684-96 [16481636.001]
  • [Cites] Med Care. 1999 Dec;37(12):1249-59 [10599606.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • (PMID = 19331713.001).
  • [ISSN] 1471-6348
  • [Journal-full-title] International journal of technology assessment in health care
  • [ISO-abbreviation] Int J Technol Assess Health Care
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101849; United States / NCI NIH HHS / CA / R01 CA101849-01A1; United States / NCI NIH HHS / CA / R01 CA101849-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS209119; NLM/ PMC2972652
  •  go-up   go-down


17. Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, English DR, Walsh MD, Clendenning M, McKeone DM, Walters RJ, Roberts A, Pearson SA, Pavluk E, Hopper JL, Gattas MR, Goldblatt J, George J, Suthers GK, Phillips KD, Woodall S, Arnold J, Tucker K, Muir A, Field M, Greening S, Gallinger S, Perrier R, Baron JA, Potter JD, Haile R, Frankel W, de la Chapelle A, Macrae F, Rosty C, Walker NI, Parry S, Young JP: Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics. PLoS One; 2010 Jul 16;5(7):e11636
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics.
  • BACKGROUND: Patients with multiple serrated polyps are at an increased risk for developing colorectal cancer (CRC).
  • Recent reports have linked cigarette smoking with the subset of CRC that develops from serrated polyps.
  • The aim of this work therefore was to investigate the association between smoking and the risk of CRC in high-risk genetics clinic patients presenting with multiple serrated polyps.
  • METHODS AND FINDINGS: We identified 151 Caucasian individuals with multiple serrated polyps including at least 5 outside the rectum, and classified patients into non-smokers, current or former smokers at the time of initial diagnosis of polyposis.
  • Cases were individuals with multiple serrated polyps who presented with CRC.
  • Controls were individuals with multiple serrated polyps and no CRC.
  • Multivariate logistic regression was performed to estimate associations between smoking and CRC with adjustment for age at first presentation, sex and co-existing traditional adenomas, a feature that has been consistently linked with CRC risk in patients with multiple serrated polyps.
  • Patients with at least one adenoma were 4 times more likely to present with CRC compared with patients without adenomas (OR = 4.09; 95%CI 1.27 to 13.14; P = 0.02).
  • CONCLUSION: A decreased odds for CRC was identified in females with multiple serrated polyps who currently smoke, independent of age and the presence of a traditional adenoma.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2007 Jan;102(1):211 [17278272.001]
  • [Cites] Hawaii Med J. 2007 May;66(5):137, 139 [17557717.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):927-46, viii [17996798.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2331-43 [17982118.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 21;99(22):1729-35 [18000222.001]
  • [Cites] Prev Med. 2007 Dec;45(6):442-6 [17719080.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):388-95 [18242207.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):617-9 [18242224.001]
  • [Cites] N Z Med J. 2007;120(1266):U2827 [18264196.001]
  • [Cites] Am J Epidemiol. 2008 May 1;167(9):1050-8 [18304959.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Jul;134(7):743-51 [18264728.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):323-4; author reply 324 [18554507.001]
  • [Cites] Pathol Res Pract. 2008;204(7):431-47 [18541388.001]
  • [Cites] Am J Surg Pathol. 2009 Apr;33(4):572-82 [19047896.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2310-7 [19661090.001]
  • [Cites] Dis Colon Rectum. 2009 Dec;52(12):1949-55 [19934914.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3362-7 [19959683.001]
  • [Cites] Am J Surg Pathol. 2010 Mar;34(3):355-63 [20118768.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):838-43 [20200438.001]
  • [Cites] Gastroenterology. 2010 May;138(5):1697-703 [20167217.001]
  • [Cites] Int J Colorectal Dis. 2010 Jun;25(6):703-12 [20213458.001]
  • [Cites] Am J Gastroenterol. 2010 Jul;105(7):1642-7 [20125129.001]
  • [Cites] Gut. 2010 Aug;59(8):1094-100 [19710031.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):323-32 [10930367.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1831-6 [11078760.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):177-84 [11176066.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] Med Sci Sports Exerc. 2002 Dec;34(12):1996-2001 [12471307.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):950-2 [8608908.001]
  • [Cites] Am J Epidemiol. 1998 May 15;147(10):903-10 [9596467.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2101-4 [15657661.001]
  • [Cites] Am J Prev Med. 2005 Feb;28(2):182-7 [15710274.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1069-75 [15793287.001]
  • [Cites] Am J Epidemiol. 2005 May 1;161(9):806-15 [15840612.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] JAMA. 2005 Nov 16;294(19):2465-73 [16287957.001]
  • [Cites] Endoscopy. 2006 Mar;38(3):266-70 [16528654.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):897-901 [16702367.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):30-9 [16831587.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1669-70; author reply 1671 [16908806.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1778-84 [17035382.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1400-7 [17101316.001]
  • [Cites] Dis Colon Rectum. 2006 Dec;49(12):1893-6 [17096180.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):656-63 [17096326.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 6;98(23):1731-8 [17148775.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2777-83 [14687832.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):223-4 [14716753.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):288-93 [14716762.001]
  • [Cites] Cancer Sci. 2004 Jan;95(1):72-6 [14720330.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 May;1(3):202-10 [15017492.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1779-84 [15330918.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2012-8 [15447765.001]
  • [Cites] Dig Liver Dis. 2004 Oct;36(10):643-5 [15506660.001]
  • [Cites] Histopathology. 1980 Mar;4(2):155-70 [7358345.001]
  • [Cites] Am J Clin Nutr. 1990 Nov;52(5):933-7 [2239771.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • (PMID = 20661287.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA123010; United States / NCI NIH HHS / CA / U01 CA097735; United States / NCI NIH HHS / CA / 1R01CA123010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2905435
  •  go-up   go-down


18. Hsu CH, Taylor JM, Long Q, Alberts DS: Analysis of colorectal adenoma recurrence data subject to informative censoring. Cancer Epidemiol Biomarkers Prev; 2009 Mar;18(3):712-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of colorectal adenoma recurrence data subject to informative censoring.
  • The treatment effect of a colorectal polyp prevention trial is often evaluated from the colorectal adenoma recurrence status at the end of the trial.
  • The method described here is illustrated with an example from a colon polyp prevention study.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Jul;89(7):845-60 [12081733.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Stat Med. 1988 Nov;7(11):1139-45 [3201039.001]
  • [Cites] Biometrics. 1992 Sep;48(3):951-9 [1420849.001]
  • [Cites] Stat Med. 1992 Sep 15;11(12):1569-78 [1439361.001]
  • [Cites] Biometrics. 1996 Mar;52(1):137-51 [8934589.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):846-53 [15928305.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Stat Med. 2006 Oct 30;25(20):3503-17 [16345047.001]
  • [Cites] Stat Med. 2007 Mar 30;26(7):1567-78 [16850435.001]
  • (PMID = 19240239.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / P30 CA023074-30; United States / NCI NIH HHS / CA / CA041108-22; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / CA041108-21; United States / NCI NIH HHS / CA / P30 CA023074-28; None / None / / P30 CA023074-30; United States / NCI NIH HHS / CA / P01 CA041108; United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / P01 CA041108-21; United States / NCI NIH HHS / CA / P01 CA041108-22; United States / NCI NIH HHS / CA / CA41108
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  • [Other-IDs] NLM/ NIHMS104698; NLM/ PMC2668929
  •  go-up   go-down


19. Miller J, Mehta N, Feldman M, Furth E, Ginsberg GG, Yang YX, Lewis JD: Findings on serial surveillance colonoscopy in patients with low-risk polyps on initial colonoscopy. J Clin Gastroenterol; 2010 Mar;44(3):e46-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Findings on serial surveillance colonoscopy in patients with low-risk polyps on initial colonoscopy.
  • GOALS: This study describes the prevalence of adenomatous polyps at serial follow-up exams after a colonoscopy finding 1 to 2 small tubular adenomas.
  • At the second and third colonoscopy, 31/88 (35.2%) patients and 26/88 (29.6%) patients had at least 1 adenoma, respectively.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):433-7 [10744815.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jan;7(1):86-92 [18829395.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1077-83 [11266371.001]
  • [Cites] Gut. 2001 Jun;48(6):812-5 [11358901.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):307-14 [11868001.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):323-33 [14991494.001]
  • [Cites] Radiology. 2004 Sep;232(3):784-90 [15247435.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1151-62 [16230069.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):546-57 [16564851.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):556-62 [16996349.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):614-26 [16996358.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2533-41 [17167136.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):42-7 [17631129.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • (PMID = 19620883.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] ENG
  • [Grant] None / None / / K24 DK078228-01; United States / NIDDK NIH HHS / DK / K24 DK078228; United States / NIDDK NIH HHS / DK / T32DK007740; United States / NIDDK NIH HHS / DK / T32 DK007740; United States / NIDDK NIH HHS / DK / DK007740-02; United States / NIDDK NIH HHS / DK / K24 DK078228-01; United States / NIDDK NIH HHS / DK / T32 DK007740-02; United States / NIDDK NIH HHS / DK / K24-DK078228
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS118008; NLM/ PMC2828518
  •  go-up   go-down


20. Freeman HJ: Heterogeneity of colorectal adenomas, the serrated adenoma, and implications for screening and surveillance. World J Gastroenterol; 2008 Jun 14;14(22):3461-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of colorectal adenomas, the serrated adenoma, and implications for screening and surveillance.
  • Current algorithms for screening and surveillance for colon cancer are valuable, but may be limited by the underlying nature of the targeted neoplastic lesions.
  • Although part of the success of adenoma removal relates to interruption of so-called "adenoma-carcinoma sequence", an alternate serrated pathway to colon cancer may pose difficulties with the ultimate results achieved by traditional colonoscopic methods.
  • The endpoint carcinoma in this unique pathway may be derived from a dysplastic serrated adenoma.
  • These tend to be located primarily in the right colon, especially in females, and are frequently associated with co-existent colon cancer.
  • Unfortunately, however, there are few, if any, other identifiable risk factors, including age or family history of colon polyps or colon cancer.
  • Screening algorithms in the future may need to be modified and individualized, depending on new information that likely will emerge on the natural history of these biologically heterogeneous lesions that differs from traditional adenomatous polyps.
  • [MeSH-major] Adenoma / diagnosis. Algorithms. Colorectal Neoplasms / diagnosis. Mass Screening / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):177-84 [11176066.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):129-60, vii-viii [18313544.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1631-4 [17067594.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1400-7 [17101316.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1491-501 [17122504.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2711-6 [17227517.001]
  • [Cites] Gut. 2007 Mar;56(3):373-9 [17005766.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):440-5 [17516746.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):947-68, viii [17996799.001]
  • [Cites] Gut. 2008 Jan;57(1):59-64 [17681999.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):21-9 [18162766.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):30-5 [18162767.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):296-303 [18223333.001]
  • [Cites] J Gastroenterol. 2008;43(1):45-50 [18297435.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • (PMID = 18567071.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2716605
  •  go-up   go-down


21. Oh K, Willett WC, Wu K, Fuchs CS, Giovannucci EL: Calcium and vitamin D intakes in relation to risk of distal colorectal adenoma in women. Am J Epidemiol; 2007 May 15;165(10):1178-86
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium and vitamin D intakes in relation to risk of distal colorectal adenoma in women.
  • The authors examined intakes of calcium and vitamin D, and interaction with retinol, in relation to risk of adenoma of the distal colon or rectum among 48,115 US women who were free of colorectal cancer or polyps, completed a food frequency questionnaire in 1980, and underwent endoscopy by 2002.
  • They documented 2,747 cases of adenoma (1,064 large, 1,531 small, 2,085 distal colon, and 779 rectal).
  • Total calcium intake was weakly associated with distal colorectal adenoma risk (multivariable relative risk (RR) for extreme quintiles = 0.88, 95% confidence interval (CI): 0.74, 1.04; p(trend) = 0.06), particularly for large adenoma (RR = 0.73, 95% CI: 0.56, 0.96; p(trend) = 0.02).
  • Total vitamin D intake was weakly associated with reduced risk of distal colorectal adenoma (RR = 0.79, 95% CI: 0.63, 0.99; p(trend) = 0.07), but more strongly with distal colon adenoma risk (RR = 0.67, 95% CI: 0.52, 0.87; p(trend) = 0.004).
  • The combinations of high vitamin D and low retinol intake (RR = 0.55, 95% CI: 0.28, 1.10) further decreased risk of distal colorectal adenoma when compared with the opposite extreme.

  • MedlinePlus Health Information. consumer health - Calcium.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379616.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK040561; None / None / / P30 DK040561-12; United States / NCI NIH HHS / CA / CA 87969; United States / NIDDK NIH HHS / DK / P30 DK040561-12; United States / NCI NIH HHS / CA / CA 55075
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium, Dietary; 11103-57-4 / Vitamin A; 1406-16-2 / Vitamin D
  •  go-up   go-down


22. Friedland S, Soetikno R, Carlisle M, Taur A, Kaltenbach T, Segall G: 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer. Gastrointest Endosc; 2005 Mar;61(3):395-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer.
  • BACKGROUND: 18-Fluorodeoxyglucose positron emission tomography (PET) is used clinically to detect recurrent colon cancer after surgical resection, but the sensitivity of PET for premalignant colon lesions and early stage colon cancer is not well defined.
  • METHODS: In a prospective study, 45 patients with a total of 58 colonic neoplasms, including premalignant polyps, premalignant, flat lesions, and early stage cancers, were evaluated by PET.
  • CONCLUSIONS: PET has limited sensitivity for flat, premalignant lesions; protruded, premalignant lesions smaller than 3 cm; and colon cancers smaller than 2 cm.
  • [MeSH-major] Adenoma / diagnostic imaging. Colonic Neoplasms / diagnostic imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Precancerous Conditions / diagnostic imaging. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15758910.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM: C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps. Pharmacogenet Genomics; 2009 Feb;19(2):113-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polyps.
  • INTRODUCTION: C-reactive protein (CRP) is a nonspecific marker of inflammation linked to cardiovascular disease and possibly colon cancer.
  • In a case-control study of adenomatous (n=491) or hyperplastic (n=184) polyps versus polyp-free controls (n=583) we investigated these SNPs in relation to colorectal polyp risk.
  • RESULTS: Individuals with 838 GC or CC genotypes had a modestly, although not statistically significantly, increased risk of adenomas (odds ratio: 1.4 95% confidence interval: 0.9-2.1) and a nearly 2-fold increased risk of concurrent adenomas and hyperplastic polyps (odds ratio: 2.0 95% confidence interval: 1.1-3.6).
  • Increased risk for concurrent adenomas and hyperplastic polyps was also observed for haplotype ACACAC.
  • We also observed interactions between UGT1A1 [TA](7) promoter repeat polymorphism and CRP tagSNPs -390C>T/A and 90A>T, in which only the homozygous variant CRP genotype was associated with increased risk of adenoma among those with the UGT1A1 6rpt/6rpt genotype (P interaction=0.02 and 0.04 for -390C>T/A and 90A>T, respectively).

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Drug Rev. 2006 Spring;24(1):33-50 [16939632.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):871-88 [16841255.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6585-9 [17085674.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5216-22 [17114654.001]
  • [Cites] Circulation. 2006 Dec 5;114(23):2458-65 [17101857.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1674-82 [17087947.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3566-9 [11325819.001]
  • [Cites] Genes Immun. 2002 Feb;3(1):14-9 [11857055.001]
  • [Cites] Atherosclerosis. 2002 May;162(1):217-9 [11947917.001]
  • [Cites] Pharmacogenomics J. 2002;2(1):43-7 [11990381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2063-9 [12842840.001]
  • [Cites] Hum Mol Genet. 2004 Jan 1;13(1):137-47 [14645206.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]
  • [Cites] JAMA. 2004 Feb 4;291(5):585-90 [14762037.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):889-93 [15159324.001]
  • [Cites] Breast Cancer Res. 2004;6(5):R488-98 [15318931.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1874-9 [15271790.001]
  • [Cites] Pharmacogenetics. 1994 Feb;4(1):39-42 [8004131.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):779-84 [8896888.001]
  • [Cites] Pharmacogenetics. 1997 Dec;7(6):485-95 [9429234.001]
  • [Cites] Br J Clin Pharmacol. 1998 Jun;45(6):525-38 [9663807.001]
  • [Cites] Pharmacogenetics. 1998 Oct;8(5):365-73 [9825828.001]
  • [Cites] Pharmacogenetics. 1999 Jun;9(3):341-9 [10471066.001]
  • [Cites] Atherosclerosis. 2005 Jan;178(1):139-45 [15585211.001]
  • [Cites] Atherosclerosis. 2005 Jan;178(1):193-8 [15585218.001]
  • [Cites] Ann Intern Med. 2005 Mar 15;142(6):425-32 [15767620.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):616-9 [15767339.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):457-60 [15770010.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 May;25(5):1051-6 [15731495.001]
  • [Cites] Am J Hum Genet. 2005 Jul;77(1):64-77 [15897982.001]
  • [Cites] J Mol Med (Berl). 2005 Jun;83(6):440-7 [15778807.001]
  • [Cites] Drug Metab Dispos. 2005 Jul;33(7):1027-35 [15843492.001]
  • [Cites] Int J Immunogenet. 2005 Aug;32(4):229-32 [16026589.001]
  • [Cites] J Epidemiol. 2005 Jun;15 Suppl 2:S185-9 [16127232.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2483-7 [16489056.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):502-8 [16537708.001]
  • [Cites] Circulation. 2006 Mar 21;113(11):1415-23 [16534007.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):690-5 [16614110.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jul;4(7):894-901 [16797247.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • (PMID = 19077918.001).
  • [ISSN] 1744-6872
  • [Journal-full-title] Pharmacogenetics and genomics
  • [ISO-abbreviation] Pharmacogenet. Genomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA89445; United States / NCI NIH HHS / CA / R01 CA59045; United States / NCI NIH HHS / CA / R25 CA094880; United States / NCI NIH HHS / CA / R01 CA089445; United States / NCI NIH HHS / CA / R01 CA114467; United States / NCI NIH HHS / CA / T32 CA009661
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 9007-41-4 / C-Reactive Protein; EC 1.14.13.- / CYP2C9 protein, human; EC 1.14.13.- / Cytochrome P-450 CYP2C9; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 2.4.1.- / UGT1A1 enzyme; EC 2.4.1.17 / Glucuronosyltransferase
  • [Other-IDs] NLM/ NIHMS133466; NLM/ PMC3690930
  •  go-up   go-down


24. Lieberman DA, Holub J, Eisen G, Kraemer D, Morris CD: Prevalence of polyps greater than 9 mm in a consortium of diverse clinical practice settings in the United States. Clin Gastroenterol Hepatol; 2005 Aug;3(8):798-805
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of polyps greater than 9 mm in a consortium of diverse clinical practice settings in the United States.
  • BACKGROUND & AIMS: Colonoscopy is often performed with the goal of identification of patients with serious colon neoplasia.
  • We determined the prevalence of colon masses or polyps greater than 9 mm on the basis of age, gender, race, and procedure indication in diverse clinical practice settings and compared occurrence in patients receiving colonoscopy for screening, surveillance, or evaluation of symptoms.
  • A multivariate model was developed to measure risk variables for a mass or polyps >9 mm.
  • Increasing age, male gender, and black race were associated with increased risk of mass or polyps >9 mm.
  • Patients with positive fecal occult blood test results, hematochezia, and anemia had lower NNE, whereas men older than 60 years receiving adenoma surveillance and patients with irritable bowel symptoms had similar NNE compared with average-risk subjects.
  • CONCLUSIONS: The prevalence of a colon lesion >9 mm varies on the basis of age, gender, race, and procedure indication.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Colonoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234009.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R33-DK61778-01; United States / NCI NIH HHS / CA / U01 CA 89389-01
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


25. Oh K, Willett WC, Fuchs CS, Giovannucci E: Dietary marine n-3 fatty acids in relation to risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev; 2005 Apr;14(4):835-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary marine n-3 fatty acids in relation to risk of distal colorectal adenoma in women.
  • Epidemiologic studies of dietary marine n-3 fatty acids and risk of colorectal cancer have been inconsistent, and their relation to risk of colorectal adenoma has not been evaluated in detail.
  • We examined dietary marine n-3 fatty acids and the ratio of marine n-3 to total n-6 fatty acids (n-3/n-6 ratio) in relation to risk of adenoma of the distal colon or rectum among 34,451 U.S. women who were initially free of colorectal cancer or polyps, who completed a semiquantitative food frequency questionnaire in 1980, and who underwent endoscopy from 1980 to 1998.
  • We documented 1,719 distal colorectal adenoma cases (705 large adenomas, 897 small adenomas, 1,280 distal colon adenomas, and 505 rectal adenomas) during 18 years of follow-up.
  • Neither dietary marine n-3 fatty acids nor n-3/n-6 ratio were associated with risk of total distal colorectal adenoma after adjustment for age and established risk factors [multivariable relative risk (RR) for extreme quintiles of dietary marine n-3 fatty acids = 1.04; 95% confidence interval (95% CI), 0.84-1.27, P(trend) = 0.66; RR for extreme quintiles of n-3/n-6 ratio = 1.02; 95% CI, 0.83-1.25; P(trend) = 0.86].
  • Similarly, no significant associations were observed separately for distal colon or rectal adenoma.
  • However, higher intake of dietary marine n-3 fatty acids was nonsignificantly but suggestively inversely associated with large adenoma (RR, 0.74; 95% CI, 0.54-1.01; P(trend) = 0.16) but directly associated with small adenoma (RR, 1.36; 95% CI, 1.02-1.81; P(trend) = 0.09).
  • Our findings do not support the hypothesis that a higher intake of marine n-3 fatty acids or a higher n-3/n-6 ratio reduces the risk of distal colorectal adenoma but are suggestive that higher intake may reduce the progression of small adenomas to large adenomas.
  • [MeSH-major] Adenoma / prevention & control. Colorectal Neoplasms / prevention & control. Diet. Fatty Acids, Omega-3 / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):406-7 [16492940.001]
  • (PMID = 15824153.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 87969; United States / NCI NIH HHS / CA / CA55075
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Omega-6; 0RBV727H71 / alpha-Linolenic Acid
  •  go-up   go-down


26. Figueiredo JC, Grau MV, Wallace K, Levine AJ, Shen L, Hamdan R, Chen X, Bresalier RS, McKeown-Eyssen G, Haile RW, Baron JA, Issa JP: Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1041-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors.
  • At a surveillance colonoscopy approximately 3 years after the qualifying exam, we obtained two biopsies of the normal-appearing mucosa from the right colon and two biopsies from the left colon.
  • CONCLUSIONS: LINE-1 methylation is not influenced by folic acid supplementation but differs by colon subsite.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2767-73 [18366060.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):359-66 [18339581.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2136-45 [18708408.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):849-53 [10952104.001]
  • [Cites] Am J Clin Nutr. 2000 Oct;72(4):998-1003 [11010943.001]
  • [Cites] Oncogene. 2001 May 28;20(24):3139-55 [11420731.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5606-11 [11929966.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1361-71 [12651628.001]
  • [Cites] Science. 2003 Apr 18;300(5618):489-92 [12702876.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1240-8 [12730865.001]
  • [Cites] Lancet. 2003 May 17;361(9370):1693-9 [12767735.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):937-44 [12771039.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):95-101 [14534800.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]
  • [Cites] Science. 2004 Mar 12;303(5664):1626-32 [15016989.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):511-9 [15066913.001]
  • [Cites] J Med Genet. 2004 Jun;41(6):454-8 [15173232.001]
  • [Cites] J Nutr Biochem. 2004 Sep;15(9):554-60 [15350988.001]
  • [Cites] Nature. 1983 Jan 6;301(5895):89-92 [6185846.001]
  • [Cites] Biochim Biophys Acta. 1983 Jun 24;740(2):212-9 [6860672.001]
  • [Cites] Am J Clin Nutr. 1992 Jan;55(1):131-8 [1728812.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5002-6 [1516055.001]
  • [Cites] Clin Chem. 1993 Feb;39(2):263-71 [8432015.001]
  • [Cites] Biochem J. 1993 Apr 1;291 ( Pt 1):145-9 [8471033.001]
  • [Cites] Am J Clin Nutr. 1995 May;61(5):1083-90 [7733033.001]
  • [Cites] Methods Enzymol. 1997;281:43-53 [9250965.001]
  • [Cites] J Nutr. 1998 Jul;128(7):1204-12 [9649607.001]
  • [Cites] Nature. 1998 Sep 3;395(6697):89-93 [9738504.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2307-12 [10344734.001]
  • [Cites] Oncogene. 2004 Nov 18;23(54):8841-6 [15480421.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):838-42 [15726099.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):938-43 [15824167.001]
  • [Cites] Gut. 2005 May;54(5):648-53 [15831910.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):981-90 [15695236.001]
  • [Cites] Clin Chem. 2005 Jul;51(7):1206-16 [15976101.001]
  • [Cites] J Nutr. 1999 Nov;129(11):1945-50 [10539767.001]
  • [Cites] Nutrition. 2000 Apr;16(4):296-302 [10758367.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8635-9 [16204030.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2703-9 [16251634.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):6823-36 [16326863.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] J Pathol. 2007 Feb;211(3):269-77 [17139617.001]
  • [Cites] PLoS One. 2007;2(5):e399 [17476321.001]
  • [Cites] Br J Nutr. 2007 Jun;97(6):1090-8 [17433124.001]
  • [Cites] BMC Cancer. 2007;7:72 [17474983.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] J Nutr. 2007 Jul;137(7):1713-7 [17585020.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1454-60 [17640302.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1724-8 [17582607.001]
  • [Cites] Epigenetics. 2007 Jan-Mar;2(1):66-8 [17965592.001]
  • [Cites] Hum Genet. 2007 Dec;122(5):505-14 [17851693.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] J Nutr. 2008 Apr;138(4):703-9 [18356324.001]
  • [Cites] Gastroenterology. 2008 Jun;134(7):1950-60, 1960.e1 [18435933.001]
  • (PMID = 19336559.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54-CA-100971; United States / NCI NIH HHS / CA / R01-CA-059005; United States / NCI NIH HHS / CA / CA059005-10; United States / NCI NIH HHS / CA / CA059005-10S1; United States / NCI NIH HHS / CA / R01 CA059005-10; United States / NCI NIH HHS / CA / R01 CA105346-04; United States / NCI NIH HHS / CA / CA059005-16; United States / NCI NIH HHS / CA / U54 CA100971-05; United States / NCI NIH HHS / CA / R01 CA059005-10S1; United States / NCI NIH HHS / CA / R01 CA105346; United States / NCI NIH HHS / CA / CA105346-04; United States / NCI NIH HHS / CA / CA100971-05; United States / NCI NIH HHS / CA / U54 CA100971; United States / NCI NIH HHS / CA / R01-CA-105346; United States / NCI NIH HHS / CA / R01 CA059005-16; United States / NCI NIH HHS / CA / R01 CA059005
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8059-24-3 / Vitamin B 6; 935E97BOY8 / Folic Acid; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ NIHMS112791; NLM/ PMC2712652
  •  go-up   go-down


27. Nagasaka T, Goel A, Notohara K, Takahata T, Sasamoto H, Uchida T, Nishida N, Tanaka N, Boland CR, Matsubara N: Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer; 2008 Jun 1;122(11):2429-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis.
  • Two methylation sensitive regions (Mp and Eh region) of MGMT promoter were investigated in 593 specimens of colorectal tissue: 233 CRCs, 104 adenomatous polyps (AP), 220 normal colonic mucosa from CRC patients (N-C) and 36 normal colonic mucosa specimens obtained from subjects without colorectal neoplasia (N-N) by combined bisulfite restriction analysis (COBRA).
  • Our data suggest that MGMT methylation may evolve and spread throughout the promoter in a stepwise manner as the colonic epithelial cells progress through the classical-adenoma-cancer multistep cascade.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5306-12 [14614014.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4842-8 [12941804.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6119-29 [2205376.001]
  • [Cites] Nucleic Acids Res. 1991 Nov 25;19(22):6163-7 [1956775.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6471-5 [1423294.001]
  • [Cites] Biochim Biophys Acta. 1994 Mar 1;1217(2):141-6 [8110828.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):594-642 [9024315.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5612-9 [9271436.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3672-7 [9288770.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2029-33 [10232580.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4584-94 [15542810.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):223-31 [15719030.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer Sci. 2005 Apr;96(4):206-11 [15819717.001]
  • [Cites] Gut. 2005 Jun;54(6):797-802 [15888787.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1073-7 [17960246.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2368-71 [10811111.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):827-30 [11221863.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4689-92 [11406538.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1300-9 [11729109.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2760-8 [11753949.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1166-70 [11861399.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):626-33 [12612901.001]
  • [Cites] Oncogene. 2003 Dec 4;22(55):8835-44 [14647440.001]
  • (PMID = 18240147.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA98572; United States / NCI NIH HHS / CA / R01 CA098572; United States / NCI NIH HHS / CA / R01-CA72851; United States / NCI NIH HHS / CA / R01 CA072851-13; United States / NCI NIH HHS / CA / R01 CA072851; United States / NCI NIH HHS / CA / R01 CA098572-05; United States / NCI NIH HHS / CA / CA098572-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 3.6.5.2 / ras Proteins; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ NIHMS187517; NLM/ PMC2851179
  •  go-up   go-down


28. Silk AW, Schoen RE, Potter DM, Finn OJ: Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol; 2009 Nov;47(1):52-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer.
  • Colorectal cancer (CRC) expresses a hypoglycosylated (abnormal) form of MUC1 different than MUC1 expressed in normal colon, which elicits antibodies in patients with CRC.
  • This form of MUC1 is expressed in other abnormal but non-malignant lesions in the colon, such as adenomatous polyps, precursors to CRC.
  • We evaluated IgM and IgG anti-MUC1 antibodies in 148 subjects with non-advanced adenomas (NAA), advanced adenomas (AA), colorectal cancer, hyperplastic polyps (HPP), and normal controls.
  • We hypothesized that the prevalence of anti-MUC1 antibodies would increase along the adenoma-carcinoma sequence as more dysplastic tissues express more abnormal MUC1.
  • We found no significant differences in the prevalence of anti-MUC1 antibodies between subjects along the adenoma-carcinoma sequence.
  • Our data support further studies into the potential role of anti-MUC1 immunity in preventing progression of premalignant colon lesions to colon cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):574-83 [10653872.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Feb 1;177(3):279-84 [17975201.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):1056-61 [10763959.001]
  • [Cites] Cancer Causes Control. 2000 May;11(5):403-11 [10877333.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):97-100 [12455059.001]
  • [Cites] Adv Immunol. 2004;82:249-93 [14975259.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt. 2):3240-5 [1192400.001]
  • [Cites] Lab Invest. 1987 Aug;57(2):193-9 [3613527.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2856-60 [7514493.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):560-4 [8813954.001]
  • [Cites] Oncol Res. 1996;8(2):53-61 [8859775.001]
  • [Cites] J Histochem Cytochem. 1997 Nov;45(11):1547-57 [9358856.001]
  • [Cites] J Gastroenterol. 1998 Jun;33(3):354-61 [9658314.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1039-48 [10424888.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1125-31 [15894662.001]
  • [Cites] Lupus. 2006;15(11):827-32 [17153858.001]
  • [Cites] Hepatology. 2007 Sep;46(3):769-75 [17654740.001]
  • [Cites] Hepatology. 2007 Dec;46(6):1828-35 [17705297.001]
  • [Cites] Turk J Gastroenterol. 2007 Dec;18(4):230-8 [18080919.001]
  • [Cites] Dig Dis Sci. 2000 Mar;45(3):494-9 [10749323.001]
  • (PMID = 19217667.001).
  • [ISSN] 1872-9142
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA056103-14; United States / NCI NIH HHS / CA / R01 CA056103; United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / R01 CA056103-14
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / MUC1 protein, human; 0 / Mucin-1
  • [Other-IDs] NLM/ NIHMS160621; NLM/ PMC2789300
  •  go-up   go-down


29. Yashiro M, Laghi L, Saito K, Carethers JM, Slezak P, Rubio C, Hirakawa K, Boland CR: Serrated adenomas have a pattern of genetic alterations that distinguishes them from other colorectal polyps. Cancer Epidemiol Biomarkers Prev; 2005 Sep;14(9):2253-6
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serrated adenomas have a pattern of genetic alterations that distinguishes them from other colorectal polyps.
  • BACKGROUND: Serrated adenomas are characterized by serrated crypts with dysplasia, and are distinguished from other polyps by their histology, but the genetic basis of serrated adenomas is unknown.
  • We investigated genetic alterations in colorectal polyps to determine if a specific pattern were associated with serrated adenomas.
  • METHODS: Sixty-six small (<10 mm) colorectal polyps were studied, including 11 hyperplastic polyps, 27 serrated adenomas, 9 tubular adenomas, 6 tubulovillous adenomas, and 3 villous adenomas.
  • Allelic imbalance of 18q was significantly more common (P < 0.05), whereas allelic imbalance of 5q and K-ras mutations were significantly less common (P < 0.05) in serrated adenomas compared with other polyps.
  • Serrated adenomas seem to evolve through a different genetic pathway than other types of polyps in the colon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172239.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090231-05; United States / NCI NIH HHS / CA / R01 CA090231; United States / NCI NIH HHS / CA / R-01 CA72851; United States / NCI NIH HHS / CA / R01 CA090231-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


30. Neri E, Faggioni L, Cini L, Bartolozzi C: Colonic polyps: inheritance, susceptibility, risk evaluation, and diagnostic management. Cancer Manag Res; 2010;3:17-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic polyps: inheritance, susceptibility, risk evaluation, and diagnostic management.
  • Up to 25% of patients with CRC have a family history for CRC, and a fraction of these patients are affected by hereditary syndromes, such as familial adenomatous polyposis, Gardner or Turcot syndromes, or hereditary nonpolyposis colorectal cancer.
  • The onset of CRC is triggered by a well-defined combination of genetic alterations, which form the bases of the adenoma-carcinoma sequence hypothesis and justify the set-up of CRC screening techniques.
  • This success of CTC is due mainly to its ability to provide cross-sectional analytical images of the entire colon and secondarily detect extracolonic findings, with minimal invasiveness and lower cost than OC, and with greater detail and diagnostic accuracy than DCBE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Jun 15;342(24):1766-72 [10852998.001]
  • [Cites] Br J Radiol. 2001 May;74(881):420-8 [11388990.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):725-31 [11440957.001]
  • [Cites] Radiology. 2002 Jun;223(3):615-9 [12034925.001]
  • [Cites] Radiology. 2003 Sep;228(3):878-85 [12954902.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jul;183(1):127-34 [15208126.001]
  • [Cites] Abdom Imaging. 2005 Jan-Feb;30(1):26-41 [15647868.001]
  • [Cites] Lancet. 2005 Jan 22-28;365(9456):305-11 [15664225.001]
  • [Cites] Ann Intern Med. 2005 Apr 19;142(8):635-50 [15838071.001]
  • [Cites] Radiology. 2005 Dec;237(3):819-33 [16237143.001]
  • [Cites] AJR Am J Roentgenol. 2006 Mar;186(3):696-702 [16498097.001]
  • [Cites] Eur Radiol. 2006 Oct;16(10):2275-83 [16703308.001]
  • [Cites] Eur Radiol. 2007 Feb;17(2):575-9 [16967260.001]
  • [Cites] Radiology. 2007 Sep;244(3):852-64 [17709833.001]
  • [Cites] Radiology. 2007 Oct;245(1):140-9 [17885187.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):948-54 [18281669.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):130-60 [18322143.001]
  • [Cites] Br J Radiol. 2009 Mar;82(975):219-27 [19064598.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Natl Compr Canc Netw. 2010 Jan;8(1):67-76; quiz 77 [20064290.001]
  • [Cites] World J Gastroenterol. 2010 Feb 28;16(8):921-6 [20180229.001]
  • [Cites] CA Cancer J Clin. 2010 Mar-Apr;60(2):99-119 [20228384.001]
  • [Cites] Am J Gastroenterol. 2010 Dec;105(12):2588-96 [20877348.001]
  • [Cites] Surg Oncol Clin N Am. 2010 Oct;19(4):693-710 [20883947.001]
  • [Cites] Gastroenterology. 1987 Nov;93(5):1009-13 [3653628.001]
  • [Cites] Mol Carcinog. 2010 Nov;49(11):974-80 [20886582.001]
  • [Cites] Radiology. 2005 Dec;237(3):893-904 [16304111.001]
  • [Cites] Jpn J Clin Oncol. 2006 Sep;36(9):582-97 [16870695.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1690-9 [17087934.001]
  • [Cites] Clin Radiol. 2007 May;62(5):424-9; discussion 430-1 [17398266.001]
  • [Cites] Pediatr Surg Int. 2007 Oct;23(10):987-90 [17665204.001]
  • [Cites] AJR Am J Roentgenol. 2007 Dec;189(6):1451-6 [18029884.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2393-401 [18768509.001]
  • [Cites] Clin Radiol. 2009 Feb;64(2):142-7 [19103343.001]
  • [Cites] Abdom Imaging. 2010 Oct;35(5):596-601 [19777290.001]
  • [Cites] J Dig Dis. 2010 Jun;11(3):148-60 [20579218.001]
  • [Cites] Br J Cancer. 2010 Aug 24;103(5):747-56 [20648013.001]
  • [Cites] Radiology. 2010 Sep;256(3):827-35 [20663975.001]
  • [Cites] J Gastrointest Surg. 2010 Dec;14(12):1943-9 [20676788.001]
  • (PMID = 21407996.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3048090
  • [Keywords] NOTNLM ; colonic polyps / colonoscopy / colorectal cancer / computed tomography colonography / double contrast barium enema
  •  go-up   go-down


31. Senapati S, Ho SB, Sharma P, Das S, Chakraborty S, Kaur S, Niehans G, Batra SK: Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon. J Clin Pathol; 2010 Aug;63(8):702-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon.
  • AIM: To determine the cellular location and expression of MUC17 mucin in specimens of normal, inflamed and neoplastic colon.
  • In various colon cancer cell lines, the MUC17 expression was examined by immunoblot analysis and normal RT-PCR.
  • Similarly, MUC17 expression was decreased in hyperplastic polyps (p=0.0003), tubular and tubulovillous adenomas (p<0.0001) and colon cancers (p<0.0001).
  • Furthermore, of eight different colon cancer cell lines, MUC17 expression was only detected in LS174T and LS180 cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hum Genet. 2001;46(1):5-20 [11289722.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 1;291(3):466-75 [11855812.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):117-29 [16831596.001]
  • [Cites] Int J Biochem Cell Biol. 2010 Jun;42(6):996-1006 [20211273.001]
  • [Cites] Trends Biochem Sci. 2010 Apr;35(4):236-45 [19913432.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1540-7 [18392050.001]
  • [Cites] J Mol Med (Berl). 2006 Dec;84(12):1055-66 [17058067.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1501-17 [17101324.001]
  • [Cites] Trends Biochem Sci. 2002 Mar;27(3):126-31 [11893509.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):417-29 [12167685.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45547-57 [12237307.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] J Biol Chem. 1989 Apr 15;264(11):6480-7 [2703501.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Aug 31;171(1):407-15 [2393399.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15294-9 [2394722.001]
  • [Cites] Am Rev Respir Dis. 1991 Sep;144(3 Pt 2):S15-8 [1892320.001]
  • [Cites] Clin Sci (Lond). 1992 Nov;83(5):623-6 [1335401.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Jul 16;224(2):397-405 [8702401.001]
  • [Cites] Nat Genet. 1996 Oct;14(2):199-202 [8841195.001]
  • [Cites] Gut. 1997 May;40(5):572-4 [9203931.001]
  • [Cites] J Immunol. 1998 Nov 15;161(10):5733-44 [9820555.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1039-48 [10424888.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23676-85 [16737958.001]
  • (PMID = 20702471.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA133774-04; United States / NCI NIH HHS / CA / R01 CA078590-13; United States / NCI NIH HHS / CA / U01 CA111294; United States / NIDDK NIH HHS / DK / R24 DK080506; United States / NCI NIH HHS / CA / CA131944-04; United States / NCI NIH HHS / CA / CA133774; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA131944; United States / NCI NIH HHS / CA / CA78590; United States / NCI NIH HHS / CA / CA133774-04; United States / NCI NIH HHS / CA / R01 CA133774; United States / NIDDK NIH HHS / DK / DK080506; United States / NCI NIH HHS / CA / CA131944; United States / NCI NIH HHS / CA / R01 CA131944-04; United States / NCI NIH HHS / CA / CA111294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MUC17 protein, human; 0 / Mucins
  • [Other-IDs] NLM/ NIHMS254309; NLM/ PMC2997570
  •  go-up   go-down


32. Tsai IC, Woolf M, Neklason DW, Branford WW, Yost HJ, Burt RW, Virshup DM: Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism. Int J Cancer; 2007 Mar 1;120(5):1005-12
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism.
  • We speculated that mutations in the autoinhibitory domain of CKIdelta/epsilon might upregulate CKIdelta/epsilon activity and hence Wnt signaling and increase the risk of adenomatous polyps and colon cancer.
  • Exons encoding the CKIepsilon and CKIdelta regulatory domains were sequenced from DNA obtained from individuals with adenomatous polyps and a family history of colon cancer unaffected by familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer (HNPCC).
  • A CKIdelta missense mutation, changing a highly conserved residue, Arg324, to His (R324H), was found in an individual with large and multiple polyps diagnosed at a relatively young age.
  • Second, CKIdelta(R324H) is more potent than wildtype CKIdelta in transformation of RKO colon cancer cells.
  • This novel human CKIdelta mutation may alter the physiological role and enhance the transforming ability of CKIdelta through a Wnt/beta-catenin independent mechanism and thereby influence colonic adenoma development.
  • [MeSH-major] Adenomatous Polyps / genetics. Casein Kinase Idelta / genetics. Colonic Neoplasms / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17131344.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-3541; United States / NCI NIH HHS / CA / P01 CA73992; United States / NCI NIH HHS / CA / P30 CA42014; United States / NCI NIH HHS / CA / R01 CA40641; United States / NCI NIH HHS / CA / R01 CA80809
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin; 4QD397987E / Histidine; 94ZLA3W45F / Arginine; EC 2.7.11.1 / Casein Kinase Idelta
  •  go-up   go-down


33. Mai PL, Korde L, Kramer J, Peters J, Mueller CM, Pfeiffer S, Stratakis CA, Pinto PA, Bratslavsky G, Merino M, Choyke P, Linehan WM, Greene MH: A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep; 2007 Mar 28;1:9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report.
  • BACKGROUND: Germ-cell testicular cancer has not been definitively linked to any known hereditary cancer susceptibility disorder.
  • His evaluation as part of an etiologic study of familial testicular cancer revealed multiple colon polyps (adenomatous, hyperplastic, and hamartomatous) first found in his 50 s, multiple lipomas, multiple hyperpigmented skin lesions, left kidney cancer diagnosed at age 64, and a growth-hormone producing pituitary adenoma with associated acromegaly diagnosed at age 64.
  • Alternatively, this family's phenotype might represent a novel neoplasm susceptibility disorder.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):629-31 [15799199.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):476-90 [15667510.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):662-6 [15185875.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):363-71 [15172357.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):984-92 [12569597.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):413-8 [10701527.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Hum Mol Genet. 2006 Feb 1;15(3):443-51 [16407372.001]
  • (PMID = 17411461.001).
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N02CP11019
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1847830
  •  go-up   go-down


34. Neklason DW, Thorpe BL, Ferrandez A, Tumbapura A, Boucher K, Garibotti G, Kerber RA, Solomon CH, Samowitz WS, Fang JC, Mineau GP, Leppert MF, Burt RW, Kuwada SK: Colonic adenoma risk in familial colorectal cancer--a study of six extended kindreds. Am J Gastroenterol; 2008 Oct;103(10):2577-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenoma risk in familial colorectal cancer--a study of six extended kindreds.
  • OBJECTIVES: Most colorectal cancers (CRCs) arise from adenomatous polyps, but the effects of CRC family history on adenoma risk are not well known.
  • Known hereditary colon cancer syndromes were clinically and genetically excluded.
  • The average age of diagnosis for colon cancer was 63 yr and advanced adenomas 56 yr.
  • Independent predictors of adenomatous polyps in the relatives were advancing age (P < 0.0001), male gender (P < 0.001), and greater degree of relation to CRC cases (P < 0.01).
  • There was no significant predilection of colorectal tumors for the right or left colon.
  • A higher degree of relationship to CRC cases was a significant predictor of having simple and advanced adenomas, but not hyperplastic polyps after adjustment for age and gender.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Familial Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Womens Health Gend Based Med. 1999 Nov;8(9):1155-66 [10595328.001]
  • [Cites] Gut. 2005 Dec;54(12):1733-40 [15955785.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:50-9; discussion 59-61 [10911905.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):837-53 [10982778.001]
  • [Cites] Gut. 2002 Feb;50(2):228-34 [11788565.001]
  • [Cites] Am J Prev Med. 2003 Feb;24(2):190-8 [12568826.001]
  • [Cites] Gut. 2003 May;52(5):747-51 [12692063.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):9-16 [15236166.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):819-25 [7055790.001]
  • [Cites] N Engl J Med. 1985 Jun 13;312(24):1540-4 [4000184.001]
  • [Cites] Genet Epidemiol. 1986;3(1):39-52 [3957003.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):533-7 [2841598.001]
  • [Cites] Am J Hum Genet. 1993 Jul;53(1):252-63 [8317490.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1618-26 [7932826.001]
  • [Cites] N Engl J Med. 1994 Dec 22;331(25):1669-74 [7969357.001]
  • [Cites] Genet Epidemiol. 1995;12(3):291-301 [7557350.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):7-12 [9649451.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Nat Genet. 1998 Dec;20(4):385-8 [9843214.001]
  • [Cites] Am J Med. 1999 Jul;107(1):68-77 [10403355.001]
  • [Cites] Cancer. 2005 May 1;103(9):1906-15 [15779016.001]
  • [Cites] JAMA. 2005 Apr 27;293(16):1979-85 [15855431.001]
  • [Cites] Eur J Cancer Prev. 2005 Aug;14(4):373-9 [16030428.001]
  • [Cites] Fam Cancer. 2005;4(3):239-44 [16136384.001]
  • [Cites] Gut. 2000 Jul;47(1):37-42 [10861262.001]
  • (PMID = 18671820.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00064; United States / NCI NIH HHS / CA / P01-CA73992; United States / NCI NIH HHS / CA / P30-CA42014; United States / NCI NIH HHS / PC / N01-PC-35141; United States / NCI NIH HHS / CA / R01-CA40641; United States / NCI NIH HHS / CA / N01PC35141; United States / NCI NIH HHS / CA / R01 CA040641-21; United States / NCI NIH HHS / CA / R01 CA040641; United States / NCI NIH HHS / CA / P01 CA073992-10; United States / NCI NIH HHS / CA / CA040641-21; United States / NCI NIH HHS / CA / P01 CA073992; United States / NCI NIH HHS / PC / N01-PC-67000; United States / NCRR NIH HHS / RR / M01 RR000064; United States / NCI NIH HHS / CA / CA073992-10; United States / NCI NIH HHS / CA / P30 CA042014
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS224182; NLM/ PMC2922112
  •  go-up   go-down


35. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, Bigler J: PTGS2 (COX-2) -765G &gt; C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):616-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs.
  • Prostaglandin H synthase 2 (PTGS2) or cyclooxygenase-2 (COX-2) has been shown to play a key role in the regulation of inflammation, and its inhibition is associated with a reduced risk of colon cancer.
  • The PTGS2 (COX-2) -765G > C promoter variant is located in a putative SP1 binding site and reduces PTGS2 expression.
  • In a Minnesota-based case-control study of cases with adenomatous (n = 494) or hyperplastic polyps (n = 186) versus polyp-free controls (n = 584), we investigated the role of the PTGS2 -765G > C promoter polymorphism.
  • For colorectal adenoma, odds ratios (OR) compared with PTGS2 -765GG as reference were GC 1.00 [95% confidence interval (95% CI), 0.74-1.35] and CC 0.53 (95% CI, 0.22-1.28).
  • For hyperplastic polyps, the comparable adjusted odds ratios were GC 0.97 (95% CI, 0.65-1.46) and CC 0.24 (95% CI, 0.05-1.11).
  • Among nonusers of aspirin or other NSAIDs, the CC genotype conferred a significant decrease in risk of adenoma (OR, 0.26; 95% CI, 0.07-0.89).
  • Use of aspirin or other NSAIDs reduced risk of adenoma only among those with the -765GG (wild type) and possibly -765CG genotypes (OR, 0.66; 95% CI, 0.48-0.92 and OR, 0.64; 95% CI, 0.40-1.02, respectively).
  • These data suggest that COX-2 expression or activity may be beneficially suppressed, and risk of colorectal polyps reduced, by aspirin or other NSAIDs in PTGS2 -765GG (wild type) individuals and by the -765 CC variant genotype in nonusers of NSAIDs.
  • [MeSH-major] Adenoma / genetics. Adenoma / prevention & control. Colorectal Neoplasms / genetics. Colorectal Neoplasms / prevention & control. Peroxidases / genetics. Polymorphism, Genetic. Prostaglandin-Endoperoxide Synthases / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858269 for PMID:15767339 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):3020
  • (PMID = 15767339.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA59045; United States / NCI NIH HHS / CA / R01CA89445
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Membrane Proteins; EC 1.11.1.- / Peroxidases; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


36. Leman ES, Schoen RE, Weissfeld JL, Cannon GW, Sokoll LJ, Chan DW, Getzenberg RH: Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res; 2007 Jun 15;67(12):5600-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.
  • Colon cancer-specific antigen (CCSA)-3 and CCSA-4 are novel colon cancer markers identified by focused proteomic analysis of nuclear structural proteins.
  • Individuals who underwent colonoscopy were classified into mutually exclusive categories, including normal colon, hyperplastic polyp, nonadvanced adenoma, and advanced adenoma.
  • The sensitivity for detection of the combined end point of colorectal cancer and advanced adenoma for CCSA-3 was 89.1% [95% confidence interval (95% CI), 76.4-96.4%] and for CCSA-4 was 84.8% (95% CI, 71.1-93.7%) and 91.3% (95% CI, 79.2-97.6%) for either marker positive.
  • The specificity in individuals with normal, hyperplastic polyps, or nonadvanced adenomas was 82.0% (95% CI, 72.4-89.4%) and 91.0% (95% CI, 83.0-96.0%) for CCSA-3 and CCSA-4, respectively.
  • [MeSH-major] Adenocarcinoma / blood. Adenoma / blood. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Colonic Neoplasms / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 3.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Schoen RE, Weissfeld JL, Sokoll LJ, Chan DW, Cannon GW, Getzenberg RH. Cancer Res. 2013 Jan 15;73(2):1034 [23271721.001]
  • (PMID = 17575123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084968
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / colon-specific antigen
  •  go-up   go-down


37. Leman ES, Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH: Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res; 2008 Mar 1;14(5):1349-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer.
  • PURPOSE: A blood test to detect colon cancer at a preventable stage would represent a major advancement.
  • We have previously identified colon cancer-specific markers using focused proteomics analysis of nuclear structural proteins.
  • Two of these markers, colon cancer-specific antigen (CCSA)-3 and CCSA-4, have been developed into blood-based markers that are able to distinguish individuals with colorectal cancer from those without.
  • CCSA-2 is a distinct novel colon cancer marker identified using focused proteomics.
  • EXPERIMENTAL DESIGN: Using an indirect ELISA on serum samples obtained from two institutions, we evaluated CCSA-2 as a serum-based colon cancer marker.
  • A total of 111 serum samples from individuals who underwent colonoscopy and were subsequently diagnosed as either being normal or having hyperplastic polyps, nonadvanced adenomas, advanced adenomas, and colorectal cancer were evaluated.
  • CCSA-2 at a cutoff of 10.8 mug/mL has overall specificity of 78.4% [95% confidence interval (95% CI), 67.3-87.1%] and sensitivity of 97.3% (95% CI, 85.8-99.5%) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations.
  • CONCLUSION: Our initial study shows that CCSA-2 is a potential serum-based marker for colon cancer detection with high sensitivity and specificity.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH. Clin Cancer Res. 2013 Jan 15;19(2):508 [23271798.001]
  • (PMID = 18316554.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / U01 CA084968-01; United States / NCI NIH HHS / CA / CA084968
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / colon cancer-specific antigen 2, human; 0 / colon-specific antigen
  • [Other-IDs] NLM/ NIHMS371863; NLM/ PMC4664476
  •  go-up   go-down


38. Heiken JP: Screening for colon cancer. Cancer Imaging; 2006;6:S13-21
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for colon cancer.
  • [MeSH-minor] Adenoma / complications. Adenoma / diagnosis. Adenoma / surgery. Barium Sulfate. Colonic Polyps / complications. Colonic Polyps / diagnosis. Colonic Polyps / surgery. Colonography, Computed Tomographic. Colonoscopy / economics. Colonoscopy / statistics & numerical data. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / epidemiology. Cost-Benefit Analysis. DNA, Neoplasm / analysis. Enema / economics. Enema / statistics & numerical data. Feces / chemistry. Gastrointestinal Hemorrhage / diagnosis. Gastrointestinal Hemorrhage / etiology. Humans. Inflammatory Bowel Diseases / complications. Inflammatory Bowel Diseases / diagnosis. Inflammatory Bowel Diseases / epidemiology. Neoplastic Syndromes, Hereditary / diagnosis. Neoplastic Syndromes, Hereditary / epidemiology. Occult Blood. Practice Guidelines as Topic. Precancerous Conditions / diagnosis. Precancerous Conditions / surgery. Predictive Value of Tests. Prospective Studies. Rectal Neoplasms / diagnosis. Rectal Neoplasms / epidemiology. Risk. Sensitivity and Specificity. Sigmoidoscopy / economics. Sigmoidoscopy / statistics & numerical data

  • International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) International Cancer Imaging Society.
  • [Cites] JAMA. 1993 Mar 10;269(10):1262-7 [8437303.001]
  • [Cites] J Clin Gastroenterol. 1992 Dec;15(4):347-51 [1294644.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] Gastroenterology. 1993 Aug;105(2):418-24 [8335197.001]
  • [Cites] Breast Cancer Res Treat. 1993;25(2):113-8 [8347843.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Scand J Gastroenterol. 1993 Oct;28(10):869-74 [8266015.001]
  • [Cites] Br J Surg. 1994 Mar;81(3):445-7 [8173926.001]
  • [Cites] Surg Endosc. 1994 Jun;8(6):672-6 [8059305.001]
  • [Cites] Am J Gastroenterol. 1995 Mar;90(3):353-65 [7872270.001]
  • [Cites] Arch Intern Med. 1995 Sep 11;155(16):1741-8 [7654107.001]
  • [Cites] Ann Intern Med. 1995 Dec 15;123(12):904-10 [7486484.001]
  • [Cites] N Engl J Med. 1996 Jan 11;334(2):82-7 [8531963.001]
  • [Cites] N Engl J Med. 1996 Jan 18;334(3):155-9 [8531970.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Gastrointest Endosc. 1996 Aug;44(2):109-11 [8858313.001]
  • [Cites] Gastrointest Endosc. 1996 Aug;44(2):112-7 [8858314.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1467-71 [8942774.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):326-31 [9207294.001]
  • [Cites] Br J Surg. 1997 Sep;84(9):1274-6 [9313712.001]
  • [Cites] Radiology. 1997 Oct;205(1):59-65 [9314963.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1406-22 [9326910.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1423-8 [9326911.001]
  • [Cites] Clin Chim Acta. 2002 Jan;315(1-2):157-68 [11728417.001]
  • [Cites] N Engl J Med. 2002 Jan 31;346(5):311-20 [11821507.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jan;12(1):41-51 [11916160.001]
  • [Cites] Am J Surg. 2002 Feb;183(2):124-31 [11918874.001]
  • [Cites] Gut. 2002 Aug;51(2):207-11 [12117881.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):96-104 [12118964.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):132-41 [12118972.001]
  • [Cites] Radiology. 2002 Aug;224(2):383-92 [12147833.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2499-507 [12385430.001]
  • [Cites] Radiology. 2002 Nov;225(2):380-90 [12409570.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):27-43 [12568442.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):44-55 [12568443.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):911-6 [12671887.001]
  • [Cites] Clin Colorectal Cancer. 2003 May;3(1):47-53 [12777192.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):304-10 [12891529.001]
  • [Cites] Endoscopy. 2003 Sep;35(9):736-42 [12929020.001]
  • [Cites] AJR Am J Roentgenol. 2003 Dec;181(6):1593-8 [14627580.001]
  • [Cites] Gut. 2003 Dec;52(12):1744-7 [14633954.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Radiology. 2003 Dec;229(3):775-81 [14657315.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):631-8 [14975961.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):64-7 [1796931.001]
  • [Cites] Am J Gastroenterol. 1991 Aug;86(8):946-51 [1858758.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):653-7 [1736103.001]
  • [Cites] Gastrointest Radiol. 1992 Winter;17(1):81-3 [1544563.001]
  • [Cites] J Natl Cancer Inst. 1992 Oct 21;84(20):1572-5 [1404450.001]
  • [Cites] Fam Pract Res J. 1992 Sep;12(3):313-20 [1414436.001]
  • [Cites] Gut. 1998 Oct;43(4):548-52 [9824584.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):344-50 [10022627.001]
  • [Cites] Scand J Gastroenterol. 1999 Jan;34(1):73-8 [10048736.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):17-23 [8978337.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):594-642 [9024315.001]
  • [Cites] Clin Radiol. 1997 Feb;52(2):142-8 [9043049.001]
  • [Cites] Ann Intern Med. 1997 Apr 1;126(7):514-9 [9092316.001]
  • [Cites] Ann Intern Med. 1997 May 15;126(10):808-10 [9148657.001]
  • [Cites] Ann Intern Med. 1997 May 15;126(10):811-22 [9148658.001]
  • [Cites] J Health Econ. 1997 Feb;16(1):1-31 [10167341.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1997 Jul;7(3):345-63 [9177139.001]
  • [Cites] Radiology. 2004 Mar;230(3):629-36 [14739311.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Apr;2(4):314-21 [15067626.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1713-9 [15082698.001]
  • [Cites] Cancer. 2004 May 15;100(10):2093-103 [15139050.001]
  • [Cites] Endoscopy. 2004 Oct;36(10):913-20 [15452790.001]
  • [Cites] Med J Aust. 1981 Jun 13;1(12):631-3 [7254054.001]
  • [Cites] J Clin Epidemiol. 1988;41(5):427-34 [3367172.001]
  • [Cites] JAMA. 1989 Jan 27;261(4):594-601 [2642564.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 3;91(5):434-7 [10070942.001]
  • [Cites] Am J Med. 1999 Jan 25;106(1A):7S-10S [10089107.001]
  • [Cites] JAMA. 1999 May 5;281(17):1611-7 [10235154.001]
  • [Cites] Gastrointest Endosc. 1999 Jun;49(6):727-30 [10343217.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1290-301 [9585611.001]
  • [Cites] Ann Intern Med. 1998 Jun 1;128(11):900-5 [9634428.001]
  • [Cites] Cancer Causes Control. 1998 Aug;9(4):455-62 [9794179.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1496-503 [10559450.001]
  • [Cites] Endoscopy. 2000 Mar;32(3):226-32 [10718388.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):557-63 [10749911.001]
  • [Cites] Radiology. 2000 May;215(2):353-7 [10796907.001]
  • [Cites] N Engl J Med. 2000 Jun 15;342(24):1766-72 [10852998.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):837-53 [10982778.001]
  • [Cites] JAMA. 2000 Oct 18;284(15):1954-61 [11035892.001]
  • [Cites] Ann Intern Med. 2000 Oct 17;133(8):573-84 [11033584.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1219-27 [11054379.001]
  • [Cites] Gut. 2001 Jun;48(6):812-5 [11358901.001]
  • [Cites] Radiology. 2001 Jun;219(3):685-92 [11376255.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2001 Mar 9;50(9):162-6 [11393486.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):858-65 [11390535.001]
  • [Cites] N Engl J Med. 2001 Aug 23;345(8):555-60 [11529208.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):38-75; quiz 77-80 [11577479.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2992-3003 [11693338.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):3009-12 [11693340.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):309-13 [10462648.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1641-6 [10511591.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1300-11 [15520999.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):192-206 [15633136.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Lancet. 2005 Jan 22-28;365(9456):305-11 [15664225.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):409-16 [15734966.001]
  • [Cites] N Engl J Med. 2005 May 19;352(20):2061-8 [15901859.001]
  • (PMID = 17114066.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 25BB7EKE2E / Barium Sulfate
  • [Other-IDs] NLM/ PMC1805055
  •  go-up   go-down


39. Bresalier RS: Early detection of and screening for colorectal neoplasia. Gut Liver; 2009 Jun;3(2):69-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently screening for adenomatous polyps and early-stage cancers is the best methodology for improving survival.
  • The increasing knowledge of CRC pathogenesis and its natural history is allowing the development of new tools to identify patients who will benefit most from colon cancer screening and the defining of appropriate surveillance intervals.
  • The guidelines for screening for colorectal neoplasia have recently been substantially revised by several organizations based on developing technologies and a growing body of data on the efficacy of CRC screening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):1-8 [19075198.001]
  • [Cites] Am J Gastroenterol. 2008 Dec;103(12):3149-51 [18853976.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):659-69 [18838717.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):627-37 [18838716.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Oct;6(10):1117-21; quiz 1064 [18691942.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Oct;6(10):1091-8 [18639495.001]
  • [Cites] Ann Intern Med. 2008 Oct 7;149(7):441-50, W81 [18838724.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1207-17 [18799557.001]
  • [Cites] Gut. 2008 Aug;57(8):1166-76 [18628378.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):130-60 [18322143.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):419-26 [18347350.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1027-35 [18319413.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1077-85 [17698067.001]
  • [Cites] N Engl J Med. 2007 Oct 4;357(14):1403-12 [17914041.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD001216 [17253456.001]
  • [Cites] Ann Intern Med. 2007 Feb 20;146(4):244-55 [17310048.001]
  • [Cites] Endoscopy. 2007 Feb;39(2):168-73 [17327977.001]
  • [Cites] Gut. 2007 Feb;56(2):210-4 [16891354.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3661-97 [16778094.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Curr Opin Gastroenterol. 2004 Jan;20(1):32-42 [15703618.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 3;91(5):434-7 [10070942.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):653-7 [1736103.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1247-56 [15131784.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1713-9 [15082698.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] JAMA. 2003 Jul 2;290(1):41-8 [12837710.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1291-300 [11965274.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):820-6 [11231935.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):392-400 [11159880.001]
  • [Cites] Ann Intern Med. 2000 Oct 17;133(8):573-84 [11033584.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1219-27 [11054379.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):837-53 [10982778.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] N Engl J Med. 2000 Jun 15;342(24):1766-72 [10852998.001]
  • [Cites] Gastroenterology. 2000 May;118(5):829-34 [10784581.001]
  • [Cites] Gastroenterology. 2009 Feb;136(2):459-70 [19026650.001]
  • (PMID = 20431727.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852697
  • [Keywords] NOTNLM ; Adenoma / Colon cancer screening / Colonoscopy / Computed tomographic colonography / Fecal occult blood testing
  •  go-up   go-down


40. Roy HK, Gomes A, Turzhitsky V, Goldberg MJ, Rogers J, Ruderman S, Young KL, Kromine A, Brand RE, Jameel M, Vakil P, Hasabou N, Backman V: Spectroscopic microvascular blood detection from the endoscopically normal colonic mucosa: biomarker for neoplasia risk. Gastroenterology; 2008 Oct;135(4):1069-78
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: We previously used a novel biomedical optics technology, 4-dimensional elastically scattered light fingerprinting, to show that in experimental colon carcinogenesis the predysplastic epithelial microvascular blood content is increased markedly.
  • Microvascular blood content was measured in 222 patients from the endoscopically normal cecum, midtransverse colon, and rectum.
  • EIBS was detectable within 30 cm from the lesion and the magnitude mirrored adenoma proximity.
  • EIBS correlated with adenoma size and was not engendered by nonneoplastic (hyperplastic) polyps.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8357-60 [11731407.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):135-42 [9918211.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):413-20 [12588199.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6D):5153-7 [14981982.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):1-8 [15017625.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1071-81; discussion 948 [15057746.001]
  • [Cites] Opt Lett. 2004 May 1;29(9):965-7 [15143642.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] Ann Intern Med. 2004 Sep 7;141(5):352-9 [15353426.001]
  • [Cites] Acta Oncol. 1992;31(1):37-40 [1586502.001]
  • [Cites] Gut. 1993 Apr;34(4):525-30 [8491402.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Dig Dis Sci. 1994 Mar;39(3):458-63 [8131680.001]
  • [Cites] Tumour Biol. 1996;17(1):58-64 [7501974.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):334-41 [9443414.001]
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2353-7 [10344743.001]
  • [Cites] Gut. 2005 May;54(5):654-60 [15831911.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2066-75 [16172211.001]
  • [Cites] JAMA. 2005 Nov 16;294(19):2465-73 [16287957.001]
  • [Cites] Appl Opt. 2006 Jan 10;45(2):335-42 [16422163.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):447-54 [16688727.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6553-62 [16818627.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2133-9 [16782971.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2533-41 [17167136.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1700-5 [17087932.001]
  • [Cites] Recent Results Cancer Res. 2007;174:219-24 [17302199.001]
  • [Cites] FEBS Lett. 2007 Aug 7;581(20):3857-62 [17658518.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Feb;6(2):220-7 [18237871.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):130-60 [18322143.001]
  • [CommentIn] Gastroenterology. 2008 Oct;135(4):1035-7 [18786535.001]
  • (PMID = 18722372.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA128641-01A1; United States / NCI NIH HHS / CA / CA109861-03; United States / NCI NIH HHS / CA / R42CA130508; United States / NCI NIH HHS / CA / CA118794-01A2; United States / NCI NIH HHS / CA / CA112315-03; United States / NCI NIH HHS / CA / R01 CA112315; United States / NCI NIH HHS / CA / CA128641-01A1; United States / NCI NIH HHS / CA / CA111257-03; United States / NCI NIH HHS / CA / U01 CA111257; United States / NCI NIH HHS / CA / R42 CA130508; United States / NCI NIH HHS / CA / R01 CA128641; United States / NCI NIH HHS / CA / R42 CA130508-01A1; United States / NCI NIH HHS / CA / R01 CA109861-03; United States / NCI NIH HHS / CA / R01 CA112315-03; United States / NCI NIH HHS / CA / CA130508-01A1; United States / NIBIB NIH HHS / EB / EB003682-03; United States / NCI NIH HHS / CA / R01 CA118794-01A2; United States / NCI NIH HHS / CA / R01 CA109861; United States / NCI NIH HHS / CA / R01 CA118794; United States / NCI NIH HHS / CA / U01 CA111257-03; United States / NIBIB NIH HHS / EB / R01 EB003682-03; United States / NIBIB NIH HHS / EB / R01 EB003682
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Hemoglobins; 9008-02-0 / deoxyhemoglobin
  • [Other-IDs] NLM/ NIHMS73576; NLM/ PMC3405534
  •  go-up   go-down


41. Kuehle CA, Langhorst J, Ladd SC, Zoepf T, Nuefer M, Grabellus F, Barkhausen J, Gerken G, Lauenstein TC: Magnetic resonance colonography without bowel cleansing: a prospective cross sectional study in a screening population. Gut; 2007 Aug;56(8):1079-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance colonography without bowel cleansing: a prospective cross sectional study in a screening population.
  • BACKGROUND AND AIMS: To evaluate the diagnostic accuracy of magnetic resonance colonography (MRC) without bowel cleansing in a screening population and compare the results to colonoscopy as a standard of reference.
  • Adenomatous polyps >5 mm were detected by means of MRC, with a sensitivity of 83.0%.
  • However, only 16 of 153 lesions <5 mm and 9 of 127 hyperplastic polyps could be visualised on magnetic resonance images.
  • It provides good accuracy for the detection of relevant (ie, adenomatous) colorectal lesions >5 mm in a screening population.
  • [MeSH-major] Colon / pathology. Colorectal Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Aged. Aged, 80 and over. Colonoscopy / methods. Contrast Media. Cross-Sectional Studies. Diatrizoate Meglumine. Feces. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / pathology. Intestinal Polyposis / diagnosis. Intestinal Polyposis / pathology. Male. Mass Screening / methods. Middle Aged. Prospective Studies. Reference Standards. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2003 Mar;98(3):578-85 [12650790.001]
  • [Cites] Invest Radiol. 2005 Feb;40(2):89-96 [15654253.001]
  • [Cites] Top Magn Reson Imaging. 2003 Oct;14(5):426-35 [14625469.001]
  • [Cites] Gut. 2003 Dec;52(12):1738-43 [14633953.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):e18 [14527992.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1713-9 [15082698.001]
  • [Cites] Eur Radiol. 2004 May;14(5):763-7 [14986051.001]
  • [Cites] Ann Intern Med. 2004 Aug 17;141(4):264-71 [15313742.001]
  • [Cites] Lancet. 2005 Jan 22-28;365(9456):305-11 [15664225.001]
  • [Cites] Radiology. 2005 Feb;234(2):452-9 [15591429.001]
  • [Cites] Dig Liver Dis. 2005 Feb;37(2):113-8 [15733524.001]
  • [Cites] Radiology. 2005 Apr;235(1):13-6 [15798163.001]
  • [Cites] Am J Prev Med. 2005 Jul;29(1):54-60 [15958253.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):684-8 [16042574.001]
  • [Cites] Endoscopy. 2005 Sep;37(9):816-20 [16116531.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):300-4 [10930364.001]
  • [Cites] Prev Med. 2000 Oct;31(4):323-34 [11006057.001]
  • [Cites] Semin Gastrointest Dis. 2000 Oct;11(4):176-84 [11057945.001]
  • [Cites] JAMA. 2001 Mar 28;285(12):1570-1 [11302136.001]
  • [Cites] Endoscopy. 2001 May;33(5):454-7 [11396767.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):310-5 [11522970.001]
  • [Cites] Rofo. 2001 Sep;173(9):785-9 [11582556.001]
  • [Cites] AJR Am J Roentgenol. 2001 Nov;177(5):975-88 [11641151.001]
  • [Cites] AJR Am J Roentgenol. 2002 Feb;178(2):283-90 [11804881.001]
  • [Cites] Gastrointest Endosc. 2002 Mar;55(3):307-14 [11868001.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jan;12(1):1-9, v [11916153.001]
  • [Cites] Eur Radiol. 2002 Jun;12(6):1410-5 [12042947.001]
  • [Cites] Radiology. 2006 Jan;238(1):143-9 [16304088.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Mar 24;55(11):308-11 [16557215.001]
  • [Cites] Radiology. 2004 Sep;232(3):735-8 [15273333.001]
  • [Cites] Br J Gen Pract. 1992 Jan;42(354):18-20 [1586526.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Lancet. 1997 May 3;349(9061):1288-91 [9142064.001]
  • [Cites] Eur J Clin Nutr. 1998 Aug;52(8):597-602 [9725661.001]
  • [Cites] Endoscopy. 1999 Feb;31(2):174-9 [10223369.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):477-84 [10508312.001]
  • [Cites] Radiology. 2004 Nov;233(2):328-37 [15358854.001]
  • [Cites] Eur Radiol. 2003 Apr;13(4):883-9 [12664130.001]
  • (PMID = 17341542.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 3X9MR4N98U / Diatrizoate Meglumine
  • [Other-IDs] NLM/ PMC1955492
  •  go-up   go-down


42. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, Xu D, Rosenberg DW: Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res; 2008 May 1;68(9):3251-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also examined the effect of mPGES-1 deletion on carcinogen-induced colon cancer.
  • Importantly, mPGES-1 deletion also blocked the nuclear accumulation of beta-catenin in ACF, confirming that beta-catenin is a critical target of PGE(2) procarcinogenic signaling in the colon.
  • [MeSH-major] Adenoma / genetics. Gene Deletion. Intestinal Neoplasms / genetics. Intramolecular Oxidoreductases / genetics
  • [MeSH-minor] Animals. Cell Proliferation. Dinoprostone / metabolism. Disease Progression. Female. Homozygote. Intestinal Polyps / genetics. Intestinal Polyps / metabolism. Intestinal Polyps / pathology. Intestine, Small / blood supply. Intestine, Small / metabolism. Isoenzymes / genetics. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Protein Transport. beta Catenin / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451151.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-114635
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / beta Catenin; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


43. Tanaka T: Colorectal carcinogenesis: Review of human and experimental animal studies. J Carcinog; 2009;8:5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The focus is on human and murine colorectal carcinogenesis and the histogenesis of this malignant disorder.
  • A summary of a model of colitis-associated colon tumorigenesis (an AOM/DSS model) will also be presented.
  • The earliest phases of colorectal oncogenesis occur in the normal mucosa, with a disorder of cell replication.
  • The large majority of colorectal malignancies develop from an adenomatous polyp (adenoma).
  • Carcinomas usually originate from pre-existing adenomas, but this does not imply that all polyps undergo malignant changes and does not exclude de novo oncogenesis.
  • Besides adenomas, there are other types of pre-neoplasia, which include hyperplastic polyps, serrated adenomas, flat adenomas and dysplasia that occurs in the inflamed colon in associated with inflammatory bowel disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Metab Rev. 1998 May;30(2):405-19 [9606610.001]
  • [Cites] Science. 1993 Jun 11;260(5114):1658-61 [8503013.001]
  • [Cites] Nature. 1993 Jul 22;364(6435):352-5 [8332195.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):260-3 [7678832.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Mol Cell Biol. 1993 Jul;13(7):4242-50 [8321226.001]
  • [Cites] Biochemistry. 1991 May 14;30(19):4637-48 [2029511.001]
  • [Cites] Hum Mol Genet. 1992 Sep;1(6):387-90 [1338760.001]
  • [Cites] Gut. 1992 Apr;33(4):524-9 [1316306.001]
  • [Cites] Carcinogenesis. 1992 Sep;13(9):1509-12 [1394832.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Cancer Res. 1991 Mar 1;51(5):1564-7 [1997197.001]
  • [Cites] Am J Clin Nutr. 1991 Jan;53(1 Suppl):226S-237S [1985392.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7937-41 [2253235.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Prog Clin Biol Res. 1988;279:319-33 [2847199.001]
  • [Cites] Pathology. 1989 Apr;21(2):138-42 [2812873.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1138-46 [2758387.001]
  • [Cites] Cancer. 1989 Aug 15;64(4):950-5 [2743285.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2373-7 [3179952.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4121-6 [3383201.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):829-34 [3338040.001]
  • [Cites] Int Rev Cytol. 1984;90:309-73 [6389415.001]
  • [Cites] Cancer Lett. 1987 Oct 30;37(2):147-51 [3677050.001]
  • [Cites] Cancer Res. 1985 Jan;45(1):1-8 [3880665.001]
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):847-51 [4053897.001]
  • [Cites] Gastroenterology. 1990 Mar;98(3):694-702 [1688816.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(1):129-34 [6430908.001]
  • [Cites] Cancer Invest. 1983;1(1):41-7 [6667399.001]
  • [Cites] J Clin Pathol. 1982 Aug;35(8):830-41 [7107955.001]
  • [Cites] Gastroenterology. 1981 Mar;80(3):578-84 [7450448.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2436-45 [200341.001]
  • [Cites] Cancer Res. 1977 Nov;37(11):4182-9 [198131.001]
  • [Cites] Virchows Arch B Cell Pathol. 1978 Dec 21;29(3):211-23 [104430.001]
  • [Cites] Biochem Pharmacol. 1977 Oct 1;26(19):1763-8 [907715.001]
  • [Cites] Lab Invest. 1974 Apr;30(4):505-13 [4363166.001]
  • [Cites] J Natl Cancer Inst. 1973 Sep;51(3):1029-39 [4355212.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):594-604 [12154352.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26281-5 [12011067.001]
  • [Cites] Lancet Oncol. 2002 Feb;3(2):83-8 [11905459.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):314-46 [11839647.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3416-21 [11248093.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2640-5 [11226292.001]
  • [Cites] BMJ. 2000 Oct 7;321(7265):886-9 [11021873.001]
  • [Cites] Drugs Aging. 2000 May;16(5):329-34 [10917070.001]
  • [Cites] Mol Med Today. 2000 Dec;6(12):462-9 [11099951.001]
  • [Cites] Chirurg. 2000 Oct;71(10):1230-4; discussion 1234-5 [11077584.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):737-45 [10980113.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3333-7 [10910033.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3323-7 [10910031.001]
  • [Cites] Gut. 2000 Jul;47(1):43-9 [10861263.001]
  • [Cites] Mt Sinai J Med. 2000 May;67(3):227-40 [10828908.001]
  • [Cites] Dis Colon Rectum. 2000 Jun;43(6):782-7 [10859077.001]
  • [Cites] Science. 2000 May 12;288(5468):1053-8 [10807576.001]
  • [Cites] Oncol Rep. 2000 May-Jun;7(3):501-8 [10767359.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):239-47 [10750661.001]
  • [Cites] Toxicol Lett. 2000 Mar 15;112-113:395-402 [10720758.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):469-76 [10688867.001]
  • [Cites] Oncogene. 2000 Jan 27;19(4):546-55 [10698524.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):183-96 [19037092.001]
  • [Cites] Gastroenterology. 2009 Feb;136(2):542-50.e6 [19103203.001]
  • [Cites] CA Cancer J Clin. 2009 Jan-Feb;59(1):27-41 [19147867.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Dec;1(7):562-7 [19139006.001]
  • [Cites] Chem Biol Interact. 2009 Jan 27;177(2):128-36 [19028472.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):780-98 [19263594.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):264-71 [19003968.001]
  • [Cites] World J Gastroenterol. 2008 Nov 21;14(43):6632-5 [19034964.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):588-94 [9484816.001]
  • [Cites] Br J Cancer. 1998;77(3):466-71 [9472645.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10 Suppl):S80-5 [9378018.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):833-9 [9060821.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):204-11 [9040192.001]
  • [Cites] Science. 1997 Feb 14;275(5302):967-9 [9020077.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):255-7 [8896552.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1001-14 [8978605.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Oct 14;227(2):553-7 [8878551.001]
  • [Cites] Cell. 1996 Oct 18;87(2):175-85 [8861902.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Oncogene. 1996 Aug 15;13(4):787-95 [8761300.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):559-68 [7513966.001]
  • [Cites] Nature. 1994 Jun 2;369(6479):411-4 [8196769.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1463-7 [7811320.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):55-71 [7600544.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5527-30 [7923190.001]
  • [Cites] Cell. 1994 Aug 12;78(3):409-24 [8062384.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8683-6 [8378348.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):162-9 [16081511.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):25-34 [16049979.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2747-54 [10348349.001]
  • [Cites] Oncogene. 1999 Apr 22;18(16):2599-606 [10353603.001]
  • [Cites] Hematol Oncol Clin North Am. 1998 Oct;12(5):963-73 [9888016.001]
  • [Cites] Biochemistry (Mosc). 1998 Jul;63(7):854-65 [9721338.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):801-4 [9796814.001]
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1146-58 [9322509.001]
  • [Cites] J Pathol. 1998 Jul;185(3):246-55 [9771477.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1998 Jun 29;353(1370):821-30 [9684279.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):495-501 [17059355.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):69-75 [16046055.001]
  • [Cites] Surg Endosc. 2006 Feb;20(2):270-3 [16341566.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):714-9 [16407113.001]
  • [Cites] Curr Biol. 2002 Feb 19;12(4):253-65 [11864565.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8664-7 [11751382.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8408-11 [11731419.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):683-94 [11463392.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):673-82 [11463391.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1874-8 [11280741.001]
  • [Cites] Curr Gastroenterol Rep. 2005 Oct;7(5):389-95 [16168238.001]
  • [Cites] Chem Biol Interact. 2005 Jun 30;155(1-2):1-9 [15904905.001]
  • [Cites] Cancer Res. 1976 May;36(5):1585-92 [178424.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt 1):2962-8 [1182690.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):483-92 [15736053.001]
  • [Cites] J Pathol. 2005 Jan;205(2):130-44 [15641015.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):229-38 [15459021.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002 [9560217.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):176-84 [10508513.001]
  • [Cites] Br J Cancer. 1975 Jul;32(1):60-77 [1174451.001]
  • [Cites] Cancer. 1975 Feb;35(2):413-8 [1111917.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):721-7 [15471557.001]
  • [Cites] Mutat Res. 2004 Nov 2;555(1-2):107-19 [15476855.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7598-611 [15314168.001]
  • [Cites] J Mol Med (Berl). 2004 Jul;82(7):434-48 [15175863.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):26-35 [15199544.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):475-80 [15182426.001]
  • [Cites] Int J Colorectal Dis. 2004 Jul;19(4):308-15 [14605835.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):29-42 [14965265.001]
  • [Cites] Cancer Sci. 2003 Nov;94(11):965-73 [14611673.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3819-25 [12839979.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2388-92 [12750256.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):347-58 [12692200.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):353-62 [12663492.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Scand J Gastroenterol Suppl. 2002;(236):48-53 [12408504.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1051-60 [12213734.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1078-83 [12201867.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Nutr Cancer. 2008;60 Suppl 1:70-80 [19003583.001]
  • [Cites] Nutr Cancer. 2008;60(5):675-84 [18791932.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):1057-63 [18375960.001]
  • [Cites] Eur J Cancer. 2008 Jul;44(10):1345-89 [18280139.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):67-96 [18053092.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Future Oncol. 2008 Feb;4(1):93-102 [18241004.001]
  • [Cites] World J Gastroenterol. 2008 Jan 21;14(3):378-89 [18200660.001]
  • [Cites] Acta Pharmacol Sin. 2008 Jan;29(1):1-20 [18158862.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9568-76 [17909068.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1659-64 [17557291.001]
  • [Cites] Cancer Biomark. 2007;3(3):135-40 [17611304.001]
  • [Cites] BMC Cancer. 2007;7:84 [17506908.001]
  • [Cites] Subcell Biochem. 2007;42:213-25 [17612053.001]
  • [Cites] Adv Exp Med Biol. 2007;595:213-26 [17569213.001]
  • [Cites] Cancer Cell Int. 2007;7:2 [17362521.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):165-71 [17366838.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Nature. 2002 May 23;417(6887):443-7 [11986622.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • (PMID = 19332896.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2678864
  •  go-up   go-down


44. Bruce WR, Cirocco M, Giacca A, Kim YI, Marcon N, Minkin S: A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation. Br J Cancer; 2005 Sep 19;93(6):639-46
Hazardous Substances Data Bank. Vitamin B1 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer risk is associated with biochemical markers for B-vitamin deficiency, insulin resistance and colonic inflammation, suggesting that these three conditions are each involved in colon carcinogenesis.
  • We therefore randomised 98 participants, with previous colonic polyps or intramucosal carcinomas, to a combined treatment of supplementary folic acid, fish oil and calcium carbonate, or placebos for 28 days.
  • This pilot study demonstrates the feasibility and practicality of clinical trials aimed at reducing diet-related biochemical risk markers for colon cancer.
  • [MeSH-minor] Adenoma / complications. Adult. Aged. Aged, 80 and over. Blood Glucose / metabolism. C-Reactive Protein / metabolism. Calcium Carbonate / administration & dosage. Dietary Supplements. Female. Fish Oils / administration & dosage. Folic Acid / administration & dosage. Humans. Male. Middle Aged. Pilot Projects. Risk Factors. Thiamine / metabolism. Treatment Outcome. Vitamin B 12 Deficiency / complications. Vitamin B 12 Deficiency / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM CARBONATE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2350S-2355S [12163691.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):687-95 [7881343.001]
  • [Cites] Cancer Causes Control. 1995 Mar;6(2):164-79 [7749056.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1760-6 [7473832.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):1013-5 [8959325.001]
  • [Cites] Gut. 1996 Nov;39(5):732-40 [9014775.001]
  • [Cites] Carcinogenesis. 1999 Dec;20(12):2209-18 [10590211.001]
  • [Cites] Am J Clin Nutr. 2000 Jan;71(1 Suppl):343S-8S [10617994.001]
  • [Cites] Scand J Gastroenterol. 1999 Dec;34(12):1216-23 [10636069.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1149-55 [10770979.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • [Cites] Gut. 2000 Jun;46(6):795-800 [10807890.001]
  • [Cites] Br J Nutr. 2000 Mar;83 Suppl 1:S85-90 [10889797.001]
  • [Cites] Am J Clin Nutr. 2000 Aug;72(2):389-94 [10919932.001]
  • [Cites] Nutr Cancer. 2000;37(1):19-26 [10965515.001]
  • [Cites] Clin Biochem. 2000 Jul;33(5):337-43 [11018684.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):184-95 [11197251.001]
  • [Cites] Circulation. 2001 Jun 12;103(23):2788-91 [11401933.001]
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1871-5 [11698351.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):393-403 [11832527.001]
  • [Cites] Diabetologia. 1997 Jun;40(6):741-2 [9222658.001]
  • [Cites] Carcinogenesis. 1997 Jul;18(7):1329-36 [9230275.001]
  • [Cites] Pharmacol Toxicol. 1998 Jan;82(1):28-33 [9527643.001]
  • [Cites] Dis Colon Rectum. 1998 Mar;41(3):316-21 [9514426.001]
  • [Cites] Nutr Rev. 1998 Sep;56(9):275-9 [9763878.001]
  • [Cites] Am J Clin Nutr. 1998 Oct;68(4):866-72 [9771864.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1679-84 [9771941.001]
  • [Cites] Diabetologia. 1998 Oct;41(10):1168-75 [9794103.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1425-31 [10426787.001]
  • [Cites] Ann Intern Med. 1999 Sep 7;131(5):331-9 [10475885.001]
  • [Cites] Heart. 1999 Oct;82(4):448-54 [10490559.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):271-8 [15765447.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):605-8 [15767337.001]
  • [Cites] Cancer Lett. 2005 Jun 8;223(2):203-9 [15896454.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1078-83 [12201867.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1421-33 [12237910.001]
  • [Cites] Nutr Cancer. 2002;43(1):1-21 [12467130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):47-56 [12540503.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Mar;27(3):347-54 [12629562.001]
  • [Cites] J Nutr Biochem. 2003 May;14(5):246-50 [12832027.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1390-3 [14641070.001]
  • [Cites] Cancer Lett. 2003 Dec 30;202(2):125-9 [14643441.001]
  • [Cites] JAMA. 2004 Feb 4;291(5):585-90 [14762037.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):279-84 [14973103.001]
  • [Cites] Am J Clin Nutr. 2004 Apr;79(4):691-7 [15051616.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6):974-82 [15159226.001]
  • [Cites] Circulation. 2004 Jun 15;109(23):2818-25 [15197153.001]
  • [Cites] Cancer. 1981 Mar 1;47(5 Suppl):1121-5 [6263443.001]
  • [Cites] Carcinogenesis. 1983 Sep;4(9):1205-7 [6883640.001]
  • [Cites] J Natl Cancer Inst. 1984 Jun;72(6):1323-5 [6587152.001]
  • [Cites] Int J Cancer. 1986 Dec 15;38(6):789-94 [3793259.001]
  • [Cites] Cancer Lett. 1990 Aug;53(1):17-25 [2397478.001]
  • [Cites] Diabetes. 1991 Feb;40(2):280-9 [1991575.001]
  • [Cites] Diabetes Care. 1991 Mar;14(3):173-94 [2044434.001]
  • [Cites] Scand J Gastroenterol. 1992 Sep;27(9):793-8 [1411288.001]
  • [Cites] JAMA. 1993 Dec 8;270(22):2693-8 [8133587.001]
  • [Cites] N Engl J Med. 1994 Jul 21;331(3):141-7 [8008027.001]
  • [Cites] Gut. 1994 Nov;35(11):1590-2 [7828978.001]
  • [Cites] Eur J Cancer Prev. 1994 Nov;3(6):473-9 [7858479.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2045-50 [7697592.001]
  • (PMID = 16136044.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Glucose; 0 / Fish Oils; 9007-41-4 / C-Reactive Protein; 935E97BOY8 / Folic Acid; H0G9379FGK / Calcium Carbonate; X66NSO3N35 / Thiamine
  • [Other-IDs] NLM/ PMC2361622
  •  go-up   go-down


45. Binda V, Pereira-Lima J, Nunes CA, Falkemberg LT, Azambuja DB, Cruz JV: Is there a role for sigmoidoscopy in symptomatic patients? Analysis of a study correlating distal and proximal colonic neoplasias detected by colonoscopy in a symptomatic population. Arq Gastroenterol; 2007 Jan-Mar;44(1):2-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for sigmoidoscopy in symptomatic patients? Analysis of a study correlating distal and proximal colonic neoplasias detected by colonoscopy in a symptomatic population.
  • AIM: To study the correlation between distal and proximal colonic neoplasias in symptomatic patients 50 years or older and patients 40 to 49 years old who underwent colonoscopy at a gastrointestinal endoscopy unit in 1999 and 2000 with the purpose to evaluate its role in a symptomatic population.
  • The distal colon was defined as the colonic segment aboral to the splenic flexure.
  • Prevalence rates for adenoma, advanced adenoma and carcinoma were 28.9%, 4.6% and 4% in the group of 830 patients 50 years or older (mean age 65 years, 491 women).
  • The finding of one small (<10 mm) adenoma in the distal bowel doubled the likelihood of finding a proximal neoplasia (OR = 2.12, 95% CI, 1.27-3.54), and multiple (OR = 3.99, 95% CI, 1.72-9.28) or advanced (OR = 3.73, 95% CI, 1.81-7.7) adenomas increased this risk even further.
  • Of the patients without adenoma or carcinoma in the distal colon, 1.93% had proximal advanced neoplasia.
  • One out of 52 patients 50 years or older with an apparently normal distal colon has advanced proximal neoplasia.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Sigmoidoscopy / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Colonic Polyps / diagnosis. Colonoscopy. Evaluation Studies as Topic. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639174.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


46. Rollison DE, Helzlsouer KJ, Lee JH, Fulp W, Clipp S, Hoffman-Bolton JA, Giuliano AR, Platz EA, Viscidi RP: Prospective study of JC virus seroreactivity and the development of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev; 2009 May;18(5):1515-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases of adenomatous polyps (n = 123) were identified from participants of the 1989 cohort who reported having a colonoscopy-detected adenoma at follow-up through 2000 with histology confirmed through medical record review.
  • One control was matched to each case on age, sex, race, and date of blood draw, and, for adenoma controls, date of endoscopy.
  • However, a statistically significant positive association between JC virus seropositivity and subsequent adenoma diagnosis was observed among males (OR, 2.31; 95% CI, 1.20-4.46), whereas a statistically significant inverse association was observed among females (OR, 0.31; 95% CI, 0.14-0.67; P for interaction = 0.01), after adjustment for baseline smoking and body mass index.
  • Future studies are needed to confirm the adenoma findings.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Aug 11;22(33):5181-91 [12910255.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6717-21 [18927316.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):483-90 [14724577.001]
  • [Cites] JAMA. 2004 Feb 4;291(5):585-90 [14762037.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):662-6 [15066935.001]
  • [Cites] Mol Cancer. 2003 Dec 12;2:41 [14672538.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1228-35 [11054380.001]
  • [Cites] J Neurovirol. 2001 Aug;7(4):345-9 [11517414.001]
  • [Cites] J Virol. 2001 Nov;75(21):10290-9 [11581397.001]
  • [Cites] Dis Markers. 2001;17(3):159-61 [11790881.001]
  • [Cites] J Neurovirol. 2002 Oct;8(5):447-51 [12402171.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7093-101 [12460931.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):268-9; author reply 269-70 [12512060.001]
  • [Cites] Clin Diagn Lab Immunol. 2003 Mar;10(2):278-85 [12626455.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):75-84 [12708728.001]
  • [Cites] J Neurovirol. 2003;9 Suppl 1:54-8 [12709873.001]
  • [Cites] J Infect Dis. 2003 May 15;187(10):1571-80 [12721937.001]
  • [Cites] J Neurovirol. 2003 Aug;9(4):498-507 [12907394.001]
  • [Cites] Prog Clin Biol Res. 1983;105:133-41 [6304749.001]
  • [Cites] Cancer Causes Control. 1991 May;2(3):193-200 [1873449.001]
  • [Cites] J Infect Dis. 1997 Dec;176(6):1618-21 [9395377.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7484-9 [10377441.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):86-91 [15690663.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):1079-85 [15868949.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):723-30 [16021515.001]
  • [Cites] Adv Exp Med Biol. 2006;577:19-45 [16626025.001]
  • [Cites] Virology. 2007 Jul 20;364(1):73-86 [17368705.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1098-102 [17471560.001]
  • [Cites] Lancet. 2008 Feb 16;371(9612):569-78 [18280327.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1028-36 [18205186.001]
  • [Cites] Cancer Causes Control. 2008 Aug;19(6):559-67 [18214695.001]
  • [Cites] J Med Virol. 2008 Oct;80(10):1828-34 [18712832.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7256-62 [14612521.001]
  • (PMID = 19383887.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA118348-01A1; United States / NCI NIH HHS / CA / R01 CA118348; United States / NCI NIH HHS / CA / 1-R01-CA118348-01; United States / NCI NIH HHS / CA / R01 CA118348-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS118566; NLM/ PMC2743003
  •  go-up   go-down


47. Roy HK, Turzhitsky V, Kim Y, Goldberg MJ, Watson P, Rogers JD, Gomes AJ, Kromine A, Brand RE, Jameel M, Bogovejic A, Pradhan P, Backman V: Association between rectal optical signatures and colonic neoplasia: potential applications for screening. Cancer Res; 2009 May 15;69(10):4476-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that LEBS signal parameters generally mirrored neoplasia progression from patients with no neoplasia, to 5 to 9 mm adenoma and to advanced adenomas.
  • Moreover, this was independent of CRC risk factors, benign colonic findings, or clinically unimportant lesions (diminutive adenomas, hyperplastic polyps).
  • In conclusion, we provide the first demonstration that LEBS-detectable alterations in the endoscopically normal rectum were associated with the presence of neoplasia located elsewhere in the colon.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 May 19;352(20):2061-8 [15901859.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20118-23 [19073935.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):961-8 [16467111.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2):566-76; quiz 588-9 [16472608.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8 [16527698.001]
  • [Cites] Arch Intern Med. 2006 Mar 27;166(6):629-34 [16567601.001]
  • [Cites] Am J Gastroenterol. 2006 Jun;101(6):1362-9 [16771962.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6553-62 [16818627.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1011-9 [17030171.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2177-9 [17101934.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2533-41 [17167136.001]
  • [Cites] Nat Med. 2007 Mar;13(3):361-6 [17334370.001]
  • [Cites] World J Gastroenterol. 2007 Mar 28;13(12):1767-9 [17465465.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):666-71 [17550745.001]
  • [Cites] Arch Intern Med. 2007 Sep 24;167(17):1822-4 [17893302.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):306-10 [18268113.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1155-62 [18483337.001]
  • [Cites] Dis Colon Rectum. 2008 Sep;51(9):1381-6 [18536963.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1207-17 [18799557.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1100-5 [18691580.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1069-78 [18722372.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):627-37 [18838716.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):3899-905 [10632318.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1499-502 [12433735.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):413-20 [12588199.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1727-30 [12702551.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1071-81; discussion 948 [15057746.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] Opt Lett. 2004 Aug 15;29(16):1906-8 [15357355.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1159-65 [15367710.001]
  • [Cites] Gut. 1993 Apr;34(4):525-30 [8491402.001]
  • [Cites] Phys Med Biol. 1997 May;42(5):803-14 [9172260.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):497-502 [9434215.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2353-7 [10344743.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):916-32 [10359544.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1670-7 [15578503.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Appl Opt. 2005 Jan 20;44(3):366-77 [15717826.001]
  • [Cites] Gut. 2005 May;54(5):654-60 [15831911.001]
  • [Cites] Opt Lett. 2005 Apr 1;30(7):741-3 [15832924.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1639-45 [16030095.001]
  • (PMID = 19417131.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA128641-01A1; United States / NCI NIH HHS / CA / U01 CA111257-05; United States / NCI NIH HHS / CA / CA112315-03; United States / NCI NIH HHS / CA / CA130508-02; United States / NCI NIH HHS / CA / R01 CA112315; United States / NCI NIH HHS / CA / CA111257-05; United States / NCI NIH HHS / CA / CA128641-01A1; United States / NCI NIH HHS / CA / R33 CA122017-03; United States / NCI NIH HHS / CA / U01 CA111257; United States / NCI NIH HHS / CA / R42 CA130508; United States / NCI NIH HHS / CA / R01 CA128641; United States / NCI NIH HHS / CA / R01 CA112315-03; United States / NCI NIH HHS / CA / R33 CA122017; United States / NIBIB NIH HHS / EB / EB003682-03; United States / NCI NIH HHS / CA / CA122017-03; United States / NCI NIH HHS / CA / R42 CA130508-02; United States / NIBIB NIH HHS / EB / R01 EB003682-03; United States / NIBIB NIH HHS / EB / R01 EB003682
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS131083; NLM/ PMC2722930
  •  go-up   go-down


48. Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG, Fidler JL, Zimmerman P, Horton KM, Coakley K, Iyer RB, Hara AK, Halvorsen RA Jr, Casola G, Yee J, Herman BA, Burgart LJ, Limburg PJ: Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med; 2008 Sep 18;359(12):1207-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of CT colonography for detection of large adenomas and cancers.
  • BACKGROUND: Computed tomographic (CT) colonography is a noninvasive option in screening for colorectal cancer.
  • However, its accuracy as a screening tool in asymptomatic adults has not been well defined.
  • METHODS: We recruited 2600 asymptomatic study participants, 50 years of age or older, at 15 study centers.
  • CT colonographic images were acquired with the use of standard bowel preparation, stool and fluid tagging, mechanical insufflation, and multidetector-row CT scanners (with 16 or more rows).
  • Radiologists trained in CT colonography reported all lesions measuring 5 mm or more in diameter.
  • Optical colonoscopy and histologic review were performed according to established clinical protocols at each center and served as the reference standard.
  • The primary end point was detection by CT colonography of histologically confirmed large adenomas and adenocarcinomas (10 mm in diameter or larger) that had been detected by colonoscopy; detection of smaller colorectal lesions (6 to 9 mm in diameter) was also evaluated.
  • RESULTS: Complete data were available for 2531 participants (97%).
  • For large adenomas and cancers, the mean (+/-SE) per-patient estimates of the sensitivity, specificity, positive and negative predictive values, and area under the receiver-operating-characteristic curve for CT colonography were 0.90+/-0.03, 0.86+/-0.02, 0.23+/-0.02, 0.99+/-<0.01, and 0.89+/-0.02, respectively.
  • The sensitivity of 0.90 (i.e., 90%) indicates that CT colonography failed to detect a lesion measuring 10 mm or more in diameter in 10% of patients.
  • The per-polyp sensitivity for large adenomas or cancers was 0.84+/-0.04.
  • The per-patient sensitivity for detecting adenomas that were 6 mm or more in diameter was 0.78.
  • CONCLUSIONS: In this study of asymptomatic adults, CT colonographic screening identified 90% of subjects with adenomas or cancers measuring 10 mm or more in diameter.
  • These findings augment published data on the role of CT colonography in screening patients with an average risk of colorectal cancer. (ClinicalTrials.gov number, NCT00084929; American College of Radiology Imaging Network [ACRIN] number, 6664. )

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Massachusetts Medical Society
  • [Cites] Radiology. 2000 May;215(2):353-7 [10796907.001]
  • [Cites] Radiology. 2005 Aug;236(2):519-26 [16040909.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):911-6 [12671887.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):311-9 [12891530.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8 [16527698.001]
  • [Cites] Radiology. 2006 May;239(2):464-71 [16569789.001]
  • [Cites] Radiology. 2006 May;239(2):313-6 [16641348.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104 [17392386.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):440-5 [17516746.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):21-9 [18162766.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Br J Radiol. 2005 Jan;78(925):22-9 [15673525.001]
  • [Cites] Lancet. 2005 Jan 22-28;365(9456):305-11 [15664225.001]
  • [Cites] J Periodontal Res. 1997 May;32(4):351-4 [9210088.001]
  • [Cites] AJR Am J Roentgenol. 1996 Mar;166(3):517-21 [8623619.001]
  • [Cites] J Clin Gastroenterol. 2004 Oct;38(9):767-71 [15365402.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1713-9 [15082698.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):631-8 [14975961.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Apr;2(4):314-21 [15067626.001]
  • [CommentIn] Ann Intern Med. 2009 Feb 17;150(4):JC2-13 [19238611.001]
  • [CommentIn] Gastroenterology. 2009 Apr;136(4):1451-3 [19233331.001]
  • [CommentIn] N Engl J Med. 2008 Sep 18;359(12):1285-7 [18799563.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2842-3; author reply 2843-4 [19115494.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2843; author reply 2843-4 [19115493.001]
  • [CommentIn] N Engl J Med. 2008 Dec 25;359(26):2842; author reply 2843-4 [19109581.001]
  • [ErratumIn] N Engl J Med. 2008 Dec 25;359(26):2853
  • (PMID = 18799557.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00084929
  • [Grant] United States / NCI NIH HHS / CA / CA080098-10; United States / NCI NIH HHS / CA / U01 CA080098; United States / NCI NIH HHS / CA / U01 CA080098-10
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS73206; NLM/ PMC2654614
  •  go-up   go-down


49. Neklason DW, Stevens J, Boucher KM, Kerber RA, Matsunami N, Barlow J, Mineau G, Leppert MF, Burt RW: American founder mutation for attenuated familial adenomatous polyposis. Clin Gastroenterol Hepatol; 2008 Jan;6(1):46-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] American founder mutation for attenuated familial adenomatous polyposis.
  • BACKGROUND & AIMS: Specific mutations in the adenomatous polyposis coli (APC) gene can lead to an attenuated form of familial adenomatous polyposis (AFAP).
  • Although AFAP mutation carriers have a 69% risk of colorectal cancer by age 80, clinical recognition remains a challenge in some cases because they present with few colonic adenomas and are difficult to distinguish clinically from patients with sporadic polyps.
  • The data show that 36.6% of the mutation-positive family members have fewer than 10 colonic adenomatous polyps, and 3 (6.8%) of these individuals were diagnosed with colorectal cancer.
  • CONCLUSIONS: In view of the apparent age of this mutation, a notable fraction of both multiple-adenoma patients and perhaps even colon cancer cases in the United States could be related to this founder mutation.
  • The colon cancer risk associated with the mutation makes genetic testing of considerable importance in patients with a personal or family history of either colonic polyps or cancer at a young age.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Sep 22;9(15):2215-21 [11001924.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):198-213 [11438509.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):127-34; discussion 134-6 [11786778.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2954-8 [11867715.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8161-6 [12034871.001]
  • [Cites] Hum Mol Genet. 2002 Nov 1;11(23):2961-7 [12393807.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Trends Biotechnol. 2003 Mar;21(3):113-6 [12628367.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Am J Hum Genet. 2003 Dec;73(6):1250-60 [14624392.001]
  • [Cites] JAMA. 2004 Feb 11;291(6):718-24 [14871915.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):444-51 [15300576.001]
  • [Cites] Hum Hered. 1971;21(6):523-42 [5149961.001]
  • [Cites] N Engl J Med. 1990 Mar 29;322(13):904-8 [2156161.001]
  • [Cites] J Med Genet. 1991 May;28(5):289-96 [1650842.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] Cell. 1993 Dec 3;75(5):951-7 [8252630.001]
  • [Cites] Hum Genet. 1994 Mar;93(3):281-6 [8125478.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] Hum Genet. 1995 Dec;96(6):705-10 [8522331.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2427-33 [8625067.001]
  • [Cites] Ann Intern Med. 1997 Apr 1;126(7):514-9 [9092316.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1290-301 [9585611.001]
  • [Cites] Nat Genet. 1998 Dec;20(4):385-8 [9843214.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1857-60 [10213492.001]
  • [Cites] Am J Med Genet. 1999 Oct 8;86(4):321-4 [10494086.001]
  • [Cites] Hum Genet. 1999 Nov;105(5):388-98 [10598803.001]
  • [Cites] Am J Hum Genet. 2000 Sep;67(3):582-90 [10924409.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 1;158(1):70-4 [15771908.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1696-716 [15887160.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):195-7 [11438508.001]
  • (PMID = 18063416.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / NCI-CN-67000; United States / NCI NIH HHS / CA / P01-CA073992; United States / NCI NIH HHS / CA / R01 CA040641-21; United States / NCI NIH HHS / CA / R01 CA040641; United States / NCI NIH HHS / CA / P01 CA073992-10; United States / NCI NIH HHS / CA / CA040641-21; United States / NCI NIH HHS / CN / N01 CN067000; United States / NCI NIH HHS / CA / R01-CA040641; United States / NCI NIH HHS / CA / P01 CA073992; United States / NCI NIH HHS / CA / CA073992-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS37623; NLM/ PMC2245898
  •  go-up   go-down


50. Chen X, Halberg RB, Burch RP, Dove WF: Intestinal adenomagenesis involves core molecular signatures of the epithelial-mesenchymal transition. J Mol Histol; 2008 Jun;39(3):283-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similarly, vimentin protein was detected in both adenomas and invasive adenocarcinomas of the human colon, but not in the normal colonic epithelium or in hyperplastic polyps.
  • Elevated vimentin expression in the adenoma was not correlated with persistent Ras signaling, but was strongly correlated with reduced proliferation indices, active Wnt signaling, and TGF-beta signaling, as demonstrated by its dependence on Smad3.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Science. 1994 May 6;264(5160):835-9 [7513443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8969-73 [8090754.001]
  • [Cites] Lancet. 1996 May 18;347(9012):1377-81 [8637346.001]
  • [Cites] Cancer Surv. 1996;27:101-25 [8909797.001]
  • [Cites] Development. 2004 Dec;131(23):5817-24 [15525667.001]
  • [Cites] Curr Opin Oncol. 2005 Jan;17(1):49-54 [15608513.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):339-47 [15668738.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2032-41 [15688013.001]
  • [Cites] Cells Tissues Organs. 2005;179(1-2):56-65 [15942193.001]
  • [Cites] Nature. 2005 Jun 23;435(7045):1126-30 [15973414.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5996-6000; discussion 6000-1 [16024596.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] Cancer Biol Ther. 2005 Apr;4(4):365-70 [15846061.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5764-74 [16123809.001]
  • [Cites] Cell Cycle. 2005 Dec;4(12):1719-21 [16294041.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5134-44 [16568079.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8319-26 [16951136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4036-41 [17360473.001]
  • [Cites] Genetics. 2007 Jun;176(2):1237-44 [17435219.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] FASEB J. 2007 Dec;21(14):3853-65 [17622569.001]
  • [Cites] Genome Biol. 2007;8(7):R131 [17615082.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Nature. 1997 Dec 4;390(6659):465-71 [9393997.001]
  • [Cites] Science. 1998 Apr 24;280(5363):596-9 [9554852.001]
  • [Cites] Cell. 1998 Sep 18;94(6):703-14 [9753318.001]
  • [Cites] J Cell Biol. 2000 Jan 10;148(1):173-88 [10629227.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3031-8 [10850453.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3053-63 [11095318.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(2):575-94 [11134344.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3508-17 [11309315.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1267-78 [11430829.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10356-61 [11526241.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):38-75; quiz 77-80 [11577479.001]
  • [Cites] Bioessays. 2001 Oct;23(10):912-23 [11598958.001]
  • [Cites] J Cell Biol. 2002 Jan 21;156(2):299-313 [11790801.001]
  • [Cites] Biochim Biophys Acta. 2002 Jun 21;1602(2):97-113 [12020798.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2658-64 [12750294.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:1-10 [12814934.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):593-7 [12841867.001]
  • [Cites] J Cell Sci. 2003 Aug 15;116(Pt 16):3269-76 [12857786.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9530-5 [12886021.001]
  • [Cites] J Clin Invest. 2003 Aug;112(4):503-16 [12925691.001]
  • [Cites] Mutat Res. 2004 Jan;566(1):9-20 [14706509.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):475-80 [15182426.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Aug;4(4):649-61 [15270668.001]
  • [Cites] Cell. 2004 Aug 6;118(3):277-9 [15294153.001]
  • [Cites] J Cell Biol. 1982 Oct;95(1):333-9 [7142291.001]
  • [Cites] Ann N Y Acad Sci. 1985;455:144-57 [3909879.001]
  • [Cites] Chest. 1992 Jun;101(6):1663-73 [1534744.001]
  • (PMID = 18327651.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084227-05; United States / NCI NIH HHS / CA / U01 CA084227; United States / NCI NIH HHS / CA / R37 CA063677; United States / NCI NIH HHS / CA / R37 CA063677-14; United States / NCI NIH HHS / CA / R37-CA63677; United States / NCI NIH HHS / CA / U01-CA-84227; United States / NCI NIH HHS / CA / U01 CA084227-05; United States / NCI NIH HHS / CA / CA063677-14
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cadherins; 0 / Fibronectins; 0 / Transcription Factors; 0 / Transforming Growth Factor beta; 0 / Vimentin; 0 / Wnt Proteins; 0 / snail family transcription factors; EC 3.6.5.2 / ras Proteins; MO0N1J0SEN / Azoxymethane
  • [Other-IDs] NLM/ NIHMS59539; NLM/ PMC2544376
  •  go-up   go-down


51. Gomes AJ, Roy HK, Turzhitsky V, Kim Y, Rogers JD, Ruderman S, Stoyneva V, Goldberg MJ, Bianchi LK, Yen E, Kromine A, Jameel M, Backman V: Rectal mucosal microvascular blood supply increase is associated with colonic neoplasia. Clin Cancer Res; 2009 May 1;15(9):3110-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We now investigate whether in situ detection of EIBS in the rectum can predict neoplasia elsewhere in the colon.
  • Logistic regression using mucosal oxyhemoglobin concentration and patient age resulted in a sensitivity of 83%, a specificity of 82%, and an area under the receiver operating characteristic curve of 0.88 for the detection of advanced adenomas.
  • CONCLUSIONS: Increased microvascular blood supply in the normal rectal mucosa is associated with the presence of clinically significant neoplasia elsewhere in the colon, supporting the development of rectal EIBS as a colon cancer risk-stratification tool.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • [Cites] Appl Opt. 2008 Nov 10;47(32):6046-57 [19002229.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Gut. 2005 May;54(5):654-60 [15831911.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):422-8 [16083699.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2329-35 [16400515.001]
  • [Cites] Appl Opt. 2006 Jan 10;45(2):335-42 [16422163.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6553-62 [16818627.001]
  • [Cites] Phys Rev Lett. 2006 Sep 29;97(13):138102 [17026078.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2177-9 [17101934.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2533-41 [17167136.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1077-85 [17698067.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):293-9 [18072273.001]
  • [Cites] J Biomed Opt. 2008 Jan-Feb;13(1):010502 [18315347.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):653-6 [10919733.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jan;12(1):1-9, v [11916153.001]
  • [Cites] J Biomed Opt. 2002 Jul;7(3):388-97 [12175288.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):413-20 [12588199.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6D):5153-7 [14981982.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 May;1(3):195-201 [15017491.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1071-81; discussion 948 [15057746.001]
  • [Cites] Opt Lett. 2004 May 1;29(9):965-7 [15143642.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] Gut. 1993 Apr;34(4):525-30 [8491402.001]
  • [Cites] Gastrointest Endosc. 1996 May;43(5):463-6 [8726758.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):931-42 [9367067.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):497-502 [9434215.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1207-17 [18799557.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1069-78 [18722372.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):135-42 [9918211.001]
  • (PMID = 19383816.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA111257-05; United States / NCI NIH HHS / CA / R42CA130508; United States / NCI NIH HHS / CA / R01CA109861; United States / NCI NIH HHS / CA / CA118794-02; United States / NCI NIH HHS / CA / CA130508-02; United States / NCI NIH HHS / CA / R01 CA112315; United States / NCI NIH HHS / CA / R01 CA118794-02; United States / NCI NIH HHS / CA / CA111257-05; United States / NCI NIH HHS / CA / R01 CA128641-02; United States / NCI NIH HHS / CA / R01 CA109861-04A1; United States / NCI NIH HHS / CA / U01 CA111257; United States / NCI NIH HHS / CA / R42 CA130508; United States / NCI NIH HHS / CA / R01 CA128641; United States / NCI NIH HHS / CA / R01CA118794; United States / NCI NIH HHS / CA / R01CA128641; United States / NCI NIH HHS / CA / CA128641-02; United States / NCI NIH HHS / CA / U01CA111257; United States / NCI NIH HHS / CA / R01 CA112315-04; United States / NCI NIH HHS / CA / R01 CA109861; United States / NCI NIH HHS / CA / R01 CA118794; United States / NCI NIH HHS / CA / R42 CA130508-02; United States / NCI NIH HHS / CA / CA109861-04A1; United States / NCI NIH HHS / CA / R01CA112315; United States / NCI NIH HHS / CA / CA112315-04
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS115833; NLM/ PMC2745222
  •  go-up   go-down


52. Lash RH, Genta RM, Schuler CM: Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol; 2010 Aug;63(8):681-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study attempts to estimate the progression rate of SSAs based upon the epidemiology of a large cohort as well as identify relationships to other colorectal polyps.
  • There were 1816 (85%) patients without dysplasia (SSA-), 257 (12%) with low-grade dysplasia (SSA-LD), 45 (2%) with high-grade dysplasia (SSA-HD) and 21 (1%) with adenocarcinoma (SSA-CA).
  • The difference in median age between almost all groups was significant (SSA-=61 years versus SSA-LD=66 years (p<0.001) vs SSA-HD=72 years (p=0.002) vs SSA-CA=76 years (p=0.07, NS)).
  • Women comprised 53% of the SSA- group (968/1816), 57% of the SSA-LD group (147/257), 69% of the SSA-HD group (31/45) and 76% of the SSA-CA group (16/21), being more likely to have high-grade dysplasia (OR 1.94, 95% CI 1.03 to 3.67) and adenocarcinoma (OR 2.80, 95% CI 1.02 to 7.68).
  • CONCLUSIONS: 1.7% of patients with mucosal polyps had SSAs (with and without dysplasia), more commonly in women and primarily in the right colon.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy. Colonoscopy. Disease Progression. Female. Humans. Intestinal Polyps / epidemiology. Intestinal Polyps / pathology. Male. Middle Aged. Prevalence. United States / epidemiology. Young Adult


53. Stoffel EM, Turgeon DK, Stockwell DH, Zhao L, Normolle DP, Tuck MK, Bresalier RS, Marcon NE, Baron JA, Ruffin MT, Brenner DE, Syngal S, Great Lakes-New England Clinical Epidemiology and Validation Center of the Early Detection Research Network: Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila); 2008 Nov;1(6):470-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Lynch syndrome (also known as hereditary nonpolyposis colon cancer) is associated with an increased risk for colorectal cancer, which can arise despite frequent colonoscopic exams.
  • We evaluated the adenoma miss rate of conventional colonoscopy in patients with Lynch syndrome, and compared the sensitivity of chromoendoscopy versus intensive inspection for detecting polyps missed by conventional colonoscopy.
  • All participants first had a conventional colonoscopy with removal of all visualized polyps.
  • Size, histology, and number of polyps detected on each exam were recorded.
  • Seventeen polyps (10 adenomas and 7 hyperplastic polyps) were identified on the first standard colonoscopies.
  • Twenty-three additional polyps (12 adenomas and 11 hyperplastic polyps) were found on the second exams, yielding an adenoma miss rate of 55%.
  • Fifteen polyps (5 adenomas and 10 hyperplastic polyps) were found in subjects who had chromoendoscopy and 8 polyps (7 adenomas and 1 hyperplastic polyp) in those who had intensive inspection.
  • Controlling for age, number of previous colonoscopies, procedure time, and prior colonic resection, chromoendoscopy detected more polyps (P = 0.04), but adenoma detection was not significantly different compared with intensive inspection (P = 0.27).

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 May;118(5):829-34 [10784581.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):880-8 [12671882.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):198-213 [11438509.001]
  • [Cites] Endoscopy. 2001 Dec;33(12):1001-6 [11740641.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Gut. 2004 Mar;53(3):376-80 [14960519.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):452-6 [15300577.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2167-73 [16181364.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Sep;3(9):897-902 [16234028.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8 [16527698.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):349-54 [16527699.001]
  • [Cites] Endoscopy. 2006 May;38(5):444-8 [16767577.001]
  • [Cites] JAMA. 2006 Sep 27;296(12):1507-17 [17003399.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1093-8 [17919485.001]
  • [Cites] Gut. 2008 Jan;57(1):65-70 [17682000.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1027-35 [18319413.001]
  • [Cites] Gut. 2002 Feb;50(2):228-34 [11788565.001]
  • [Cites] Gastrointest Endosc. 2002 Sep;56(3):333-8 [12196768.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1657-65 [11375947.001]
  • (PMID = 19138994.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA113433; United States / NCI NIH HHS / CA / K07 CA 120448-01-A2; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / P30 CA46592; United States / NCI NIH HHS / CA / CA 86400; United States / NCI NIH HHS / CA / CA120448-02; United States / NCI NIH HHS / CA / U01 CA086400; United States / NCI NIH HHS / CA / K07 CA120448; United States / NCI NIH HHS / CA / K07 CA120448-02
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS98608; NLM/ PMC2671076
  •  go-up   go-down


54. Meng W, Cai SR, Zhou L, Dong Q, Zheng S, Zhang SZ: Performance value of high risk factors in colorectal cancer screening in China. World J Gastroenterol; 2009 Dec 28;15(48):6111-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We compared the performance value of the immunochemical fecal occult blood test (iFOBT) and other high risk factors questionnaire in a population sample of 13 214 community residents who completed both the iFOBT and questionnaire investigation.
  • The iFOBT had the highest sensitivity, lowest number of extra false positive results associated with the detection of one extra abnormality for screening advanced neoplasias and adenomas.
  • A history of chronic cholecystitis or cholecystectomy, chronic appendicitis or appendectomy, and chronic diarrhea also had a higher sensitivity than a history of adenomatous polyps in screening for advanced neoplasias and adenomas.
  • The sensitivity of a history of chronic cholecystitis or cholecystectomy was highest among the 10 high risk factors in screening for non-adenomatous polyps.
  • A history of chronic appendicitis or appendectomy, chronic constipation, chronic diarrhea, mucous and bloody stool, CRC in first degree relatives, malignant tumor and a positive iFOBT also had higher sensitivities than a history of adenomas polyps in screening for non-adenomatous polyps.
  • Except for a history of malignant tumor in screening for non-adenomatous polyps, the gain in sensitivity was associated with an increase in extra false positive results associated with the detection of one extra abnormality.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Colonic Polyps / diagnosis. Colorectal Neoplasms / diagnosis. Mass Screening

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2005 Aug;100(8):1813-20 [16086719.001]
  • [Cites] J Clin Epidemiol. 1997 Nov;50(11):1211-7 [9393377.001]
  • [Cites] Cancer Detect Prev. 2007;31(1):3-11 [17289293.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104 [17392386.001]
  • [Cites] Gut. 2007 Jul;56(7):965-7 [17303595.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2304-12 [17570205.001]
  • [Cites] Gut. 2008 Aug;57(8):1166-76 [18628378.001]
  • [Cites] World J Gastroenterol. 2009 Mar 7;15(9):1085-92 [19266601.001]
  • [Cites] World J Gastroenterol. 2009 Aug 21;15(31):3920-5 [19701973.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):557-63 [10749911.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] N Engl J Med. 2001 Aug 23;345(8):607-8 [11529216.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):542-7 [11522737.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):38-75; quiz 77-80 [11577479.001]
  • [Cites] J Clin Microbiol. 2001 Nov;39(11):3927-37 [11682509.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):40-3 [11863108.001]
  • [Cites] Gut. 2002 Aug;51(2):207-11 [12117881.001]
  • [Cites] Gut. 2002 Oct;51 Suppl 5:V21-7 [12221036.001]
  • [Cites] Dis Colon Rectum. 2003 Jan;46(1):51-8 [12544522.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):79-83 [12556963.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):1-8 [15017625.001]
  • [Cites] Rom J Gastroenterol. 2004 Sep;13(3):187-93 [15470530.001]
  • [Cites] Gut. 1980 Dec;21(12):1090-2 [7461469.001]
  • [Cites] Histopathology. 1983 Sep;7(5):719-28 [6195073.001]
  • [Cites] Gut. 1986 Oct;27(10):1181-5 [3781331.001]
  • [Cites] Am J Epidemiol. 1987 Apr;125(4):672-8 [3826045.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Gastroenterol Clin Biol. 1991;15(8-9):594-9 [1752369.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):130-41 [8514030.001]
  • [Cites] Scand J Gastroenterol. 1996 Feb;31(2):160-9 [8658039.001]
  • [Cites] J Med Screen. 1996;3(2):63-5 [8849761.001]
  • [Cites] Epidemiology. 1997 Jan;8(1):104-6 [9116081.001]
  • [Cites] Gut. 2007 Feb;56(2):210-4 [16891354.001]
  • (PMID = 20027686.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2797670
  •  go-up   go-down


55. Robertson DJ, Burke CA, Welch HG, Haile RW, Sandler RS, Greenberg ER, Ahnen DJ, Bresalier RS, Rothstein RI, Cole B, Mott LA, Baron JA: Using the results of a baseline and a surveillance colonoscopy to predict recurrent adenomas with high-risk characteristics. Ann Intern Med; 2009 Jul 21;151(2):103-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using the results of a baseline and a surveillance colonoscopy to predict recurrent adenomas with high-risk characteristics.
  • BACKGROUND: Suggested intervals for postpolypectomy surveillance colonoscopy are currently based on the adenoma findings from the most recent examination.
  • OBJECTIVE: To determine the risk for clinically significant adenoma recurrence on the basis of the results of 2 previous colonoscopies.
  • PATIENTS: Participants in an adenoma chemoprevention trial in which all participants had 1 or more adenoma found on complete colonoscopy at entry.
  • For this analysis, only participants whose qualifying adenoma was their first were included.
  • MEASUREMENTS: Proportion of patients with high-risk findings at the third study colonoscopy--either at least 1 advanced (> or = 1 cm or advanced histology) adenoma or multiple (> or = 3) adenomas.
  • LIMITATION: This observational study cannot specifically examine adenoma recurrence risk at intervals suggested for patients with low-risk adenomas (for example, 5 years vs. 10 years).

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2007 Oct;133(4):1077-85 [17698067.001]
  • [Cites] Ann Intern Med. 2008 Mar 18;148(6):419-26 [18347350.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):130-60 [18322143.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1218-24 [18799558.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jan;7(1):86-92 [18829395.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 May;7(5):562-7; quiz 497 [19138760.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1084-91; discussion 1091-2 [10950006.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3053-63 [11095318.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1077-83 [11266371.001]
  • [Cites] Gut. 2002 Oct;51 Suppl 5:V6-9 [12221031.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1237-46 [12818263.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):323-33 [14991494.001]
  • [Cites] Ann Intern Med. 2004 Aug 17;141(4):264-71 [15313742.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] N Engl J Med. 1993 Apr 1;328(13):901-6 [8446136.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):13-8 [9649453.001]
  • [Cites] Gastrointest Endosc. 2005 Dec;62(6):875-83 [16301030.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):546-57 [16564851.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):614-26 [16996358.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • (PMID = 19620162.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA059005; United States / NCI NIH HHS / CA / R01 CA059005-06A1; United States / NCI NIH HHS / CA / U01 CA046927; United States / NCI NIH HHS / CA / R01 CA 59005
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS138475; NLM/ PMC2779048
  •  go-up   go-down


56. Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Lamerato LE, Crawford ED, Kvale P, Fouad M, Hickey T, Riley T, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD: Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst; 2010 Apr 21;102(8):538-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subjects with polyps or mass lesions detected by FSG were referred to their physicians for diagnostic workup, the cost of which was not covered by PLCO.
  • We used log binomial modeling with adjustment for age, education, sex, body mass index, smoking, family history of colorectal cancer, colon examination within previous 3 years, personal history of polyps, and screening center to examine whether utilization of diagnostic colonoscopy and yield of neoplasia differed by race.
  • Overall, among subjects with diagnostic colonoscopy (n = 10 424), there was no statistically significant difference by race in the prevalence of adenoma, advanced adenoma, advanced pathology in small adenomas (high-grade dysplasia or villous histology in adenomas <10 mm), or colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2007 Apr 15;165(8):874-81 [17244633.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20 [16106026.001]
  • [Cites] J Natl Med Assoc. 2007 Jul;99(7):723-8 [17668638.001]
  • [Cites] J Natl Med Assoc. 2007 Jul;99(7):733-48 [17668639.001]
  • [Cites] Postgrad Med J. 2007 Sep;83(983):583-9 [17823224.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Natl Med Assoc. 2008 Mar;100(3):291-8 [18390022.001]
  • [Cites] J Gen Intern Med. 2008 May;23(5):699-705 [18338215.001]
  • [Cites] J Natl Cancer Inst. 2008 Jul 16;100(14):1003-12 [18612132.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Sep;6(9):1011-5 [18558514.001]
  • [Cites] JAMA. 2008 Sep 24;300(12):1417-22 [18812532.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1100-5 [18691580.001]
  • [Cites] J Natl Med Assoc. 2008 Dec;100(12):1441-4 [19110912.001]
  • [Cites] Arch Surg. 2009 Jan;144(1):14-8 [19153319.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2170-5 [19622721.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S [11189683.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):379S-389S [11189689.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1160-7 [12165641.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):213-4; author reply 214-5 [14718224.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):997-1000 [3719563.001]
  • [Cites] Cancer Nurs. 1995 Oct;18(5):385-92 [7585493.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2312-20 [9635522.001]
  • [Cites] JAMA. 1998 Nov 18;280(19):1690-1 [9832001.001]
  • [Cites] Cell Oncol. 2007;29(3):185-94 [17452771.001]
  • [Cites] Arch Intern Med. 2005 Oct 10;165(18):2129-35 [16217003.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Aug;3(8):792-7 [16234008.001]
  • [Cites] Am J Gastroenterol. 2006 Apr;101(4):823-30 [16494591.001]
  • [Cites] Cancer. 2006 Sep 1;107(5 Suppl):1153-61 [16862554.001]
  • [Cites] Cancer. 2006 Oct 15;107(8 Suppl):2043-51 [16977600.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):612-20 [17186529.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):515-23; discussion 514 [15743345.001]
  • [Cites] Am J Psychiatry. 2005 Jul;162(7):1336-43 [15994717.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 6;97(13):989-97 [15998952.001]
  • [CommentIn] J Natl Cancer Inst. 2010 Apr 21;102(8):511-3 [20357246.001]
  • (PMID = 20357245.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-25524; United States / NCI NIH HHS / CN / N01-CN-25513; United States / NCI NIH HHS / CN / N01-CN-25511; United States / NCI NIH HHS / CN / N01-CN-75022; United States / NCI NIH HHS / CN / N01-CN-25514; United States / NCI NIH HHS / CN / N01-CN-25512; United States / NCI NIH HHS / CN / N01-CN-25515; United States / NCI NIH HHS / CA / K01 CA127118; United States / NCI NIH HHS / CA / R01 CA151736; United States / NCI NIH HHS / CN / N01-CN-25404; United States / NCI NIH HHS / CN / N01-CN-25516; United States / NCI NIH HHS / CN / N01-CN-25476; United States / NCI NIH HHS / CN / N01-CN-25518; United States / NCI NIH HHS / CA / U01 CA151736; United States / NCI NIH HHS / CN / N01-CN-25522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2857802
  •  go-up   go-down


57. Burke CA: Colonic complications of obesity. Gastroenterol Clin North Am; 2010 Mar;39(1):47-55
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Obesity is a risk factor for colorectal cancer and adenomatous polyps.
  • [MeSH-minor] Adenoma / epidemiology. Animals. Body Mass Index. Colonoscopy. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / physiopathology. Comorbidity. Diverticulitis, Colonic / epidemiology. Humans. Insulin Resistance / physiology. Intra-Abdominal Fat / physiopathology. Leptin / physiology. Metabolic Syndrome X / epidemiology. Metabolic Syndrome X / physiopathology

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20202578.001).
  • [ISSN] 1558-1942
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


58. Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W, Desvergne B, Dey SK, DuBois RN: Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A; 2006 Dec 12;103(50):19069-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we present genetic and pharmacologic evidence demonstrating that deletion of PPARdelta decreases intestinal adenoma growth in Apc(Min/+) mice and inhibits tumor-promoting effects of a PPARdelta agonist GW501516.
  • More importantly, we found that activation of PPARdelta up-regulated VEGF in colon carcinoma cells.
  • VEGF directly promotes colon tumor epithelial cell survival through activation of PI3K-Akt signaling.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1999 Oct 29;99(3):335-45 [10555149.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Biochem Biophys Res Commun. 2000 May 19;271(3):571-4 [10814503.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5119-28 [10866668.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13275-80 [11087869.001]
  • [Cites] J Invest Dermatol. 2000 Dec;115(6):1000-7 [11121133.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2598-603 [11226285.001]
  • [Cites] Cell Growth Differ. 2001 Mar;12(3):129-35 [11306513.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5306-11 [11309497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62 [11553814.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):303-8 [11756685.001]
  • [Cites] Acta Biochim Pol. 2000;47(4):1147-57 [11996104.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3282-8 [12036946.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21341-5 [11927585.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):721-33 [12419217.001]
  • [Cites] Cell. 2003 Apr 18;113(2):159-70 [12705865.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 22;308(2):361-8 [12901877.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):257-65 [12943711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15924-9 [14676330.001]
  • [Cites] Nat Med. 2004 Mar;10(3):245-7 [14758356.001]
  • [Cites] Nat Med. 2004 Apr;10(4):355-61 [15057233.001]
  • [Cites] Nat Med. 2004 May;10(5):481-3 [15048110.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3162-70 [15126355.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):285-95 [15380519.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] Nat Med. 1995 Oct;1(10):1024-8 [7489357.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):728-33 [9973224.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16349-54 [10347193.001]
  • [Cites] J Pathol. 1999 Aug;188(4):369-77 [10440746.001]
  • [Cites] Urology. 1999 Sep;54(3):567-72 [10475375.001]
  • [Cites] Oncogene. 2004 Nov 25;23(55):8992-6 [15480419.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1822-9 [15753380.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2119-27 [16075056.001]
  • [Cites] Pharmacogenet Genomics. 2006 Jan;16(1):43-50 [16344721.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):937-45 [16355211.001]
  • [Cites] Biochem J. 2006 Apr 1;395(1):81-8 [16343055.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(8):3266-81 [16581799.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):748-53 [10762747.001]
  • (PMID = 17148604.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 77839; United States / NIDDK NIH HHS / DK / R01 DK 62112; United States / NICHD NIH HHS / HD / R37 HD 12304; United States / NIDDK NIH HHS / DK / R37 DK 47297; United States / NICHD NIH HHS / HD / P30 HD033994; United States / NICHD NIH HHS / HD / R37 HD012304; United States / NCI NIH HHS / CA / P01 CA077839; United States / NCI NIH HHS / CA / P30 CA 068485; United States / NCI NIH HHS / CA / P30 CA068485; United States / NIDDK NIH HHS / DK / R37 DK047297; United States / NIDDK NIH HHS / DK / R01 DK062112; United States / NICHD NIH HHS / HD / U54 HD033994
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GW 501516; 0 / PPAR delta; 0 / Thiazoles; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC1748178
  •  go-up   go-down


59. Michels KB, Giovannucci E, Chan AT, Singhania R, Fuchs CS, Willett WC: Fruit and vegetable consumption and colorectal adenomas in the Nurses' Health Study. Cancer Res; 2006 Apr 1;66(7):3942-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the association between fruit and vegetable consumption and the prevalence and incidence of adenomas of the distal colon and rectum in the Nurses' Health Study (NHS).
  • Consumption of fruits and vegetables was assessed in 1980, 1984, 1986, 1990, and 1994 using a semiquantitative food frequency questionnaire; 1,720 prevalent cases of adenoma of the distal colon and rectum were diagnosed between 1980 and 1998.
  • Frequent consumption of fruit was inversely related to the risk of being diagnosed with polyps, whereas little association was found for vegetable consumption.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585224.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK040561; None / None / / P30 DK040561-11; United States / NCI NIH HHS / CA / CA 87969; United States / NIDDK NIH HHS / DK / P30 DK040561-11; United States / NIDDK NIH HHS / DK / DK 54900
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Buchanan DD, Roberts A, Walsh MD, Parry S, Young JP: Lessons from Lynch syndrome: a tumor biology-based approach to familial colorectal cancer. Future Oncol; 2010 Apr;6(4):539-49
Genetic Alliance. consumer health - Lynch syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two most common epithelial lesions are the adenoma and the serrated polyp.
  • CRC is also one of the most familial of the common cancers, and just as there are syndromes associated with increased risk of CRC arising in adenomas, there are also syndromes with increased CRC risk associated with serrated polyps.
  • Lynch syndrome CRC arises almost exclusively within adenomatous precursor lesions, in contrast with familial serrated neoplasia where at least half of the cancers develop in serrated polyps.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Familial Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2008;204(7):431-47 [18541388.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1774-80 [18628431.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Sep;6(9):1011-5 [18558514.001]
  • [Cites] Dig Dis Sci. 1981 Jan;26(1):85-9 [7460710.001]
  • [Cites] Gastrointest Radiol. 1981;6(4):333-5 [7308714.001]
  • [Cites] Am J Surg Pathol. 1987 Apr;11(4):323-7 [3565675.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Fam Cancer. 2008;7(4):281-5 [18176851.001]
  • [Cites] Cancer Lett. 2009 Jan 18;273(2):221-4 [18778891.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2014-8 [19013464.001]
  • [Cites] Am J Surg Pathol. 2009 Apr;33(4):572-82 [19047896.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2407-8 [19406141.001]
  • [Cites] Gastroenterology. 2009 Aug;137(2):404-9 [19540838.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2310-7 [19661090.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1309-13 [11005503.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):177-84 [11176066.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):858-66 [11978509.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Gut. 2004 Apr;53(4):573-80 [15016754.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):423-34 [15087661.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1779-84 [15330918.001]
  • [Cites] Surg Oncol Clin N Am. 2009 Oct;18(4):599-610 [19793568.001]
  • [Cites] Fam Cancer. 2009;8(4):313-23 [19241144.001]
  • [Cites] Dis Colon Rectum. 2009 Dec;52(12):1949-55 [19934914.001]
  • [Cites] Gut. 2010 Aug;59(8):1094-100 [19710031.001]
  • [Cites] Gut. 2000 Jul;47(1):37-42 [10861262.001]
  • [Cites] Gut. 2000 Jul;47(1):43-9 [10861263.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):323-32 [10930367.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2012-8 [15447765.001]
  • [Cites] Pathol Annu. 1977;12 Pt 1:147-70 [917590.001]
  • [Cites] Dis Colon Rectum. 1979 Apr;22(3):152-6 [446245.001]
  • [Cites] Histopathology. 1980 Mar;4(2):155-70 [7358345.001]
  • [Cites] Histopathology. 1988 Dec;13(6):700-2 [2466756.001]
  • [Cites] Lancet. 1995 Nov 4;346(8984):1200-1 [7475662.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] J Pathol. 1996 May;179(1):20-5 [8691339.001]
  • [Cites] J Mol Med (Berl). 1996 Sep;74(9):547-51 [8892060.001]
  • [Cites] Pathology. 1997 Feb;29(1):28-33 [9094174.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1758-62 [9392616.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1999 Mar;28(3):327-32 [10067739.001]
  • [Cites] J Am Coll Surg. 1999 May;188(5):503-7 [10235578.001]
  • [Cites] J Clin Pathol. 1999 Jan;52(1):5-9 [10343605.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2101-4 [15657661.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):254-63 [15765445.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1069-75 [15793287.001]
  • [Cites] JAMA. 2005 Apr 27;293(16):1979-85 [15855431.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6063-9 [16024606.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7304-10 [16243801.001]
  • [Cites] Endoscopy. 2006 Mar;38(3):266-70 [16528654.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):897-901 [16702367.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):30-9 [16831587.001]
  • [Cites] World J Gastroenterol. 2006 Aug 21;12(31):4943-50 [16937488.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1239-43 [17031395.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1400-7 [17101316.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2270-3 [17119056.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1491-501 [17122504.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 21;99(4):261-3 [17312298.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 21;99(4):291-9 [17312306.001]
  • [Cites] J Pathol. 2007 Aug;212(4):378-85 [17503413.001]
  • [Cites] Fam Cancer. 2007;6(3):301-10 [17453358.001]
  • [Cites] Semin Oncol. 2007 Oct;34(5):425-7 [17920898.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):927-46, viii [17996798.001]
  • [Cites] N Z Med J. 2007;120(1266):U2827 [18264196.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):25-46, v [18313538.001]
  • [Cites] Am J Epidemiol. 2008 May 1;167(9):1050-8 [18304959.001]
  • (PMID = 20373868.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA123010; United States / NCI NIH HHS / CA / R01 CA123010-01A1; United States / NCI NIH HHS / CA / U01 CA097735; United States / NCI NIH HHS / CA / 1R01CA123010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Number-of-references] 70
  • [Other-IDs] NLM/ NIHMS207227; NLM/ PMC2896690
  •  go-up   go-down


61. Neklason DW, Tuohy TM, Stevens J, Otterud B, Baird L, Kerber RA, Samowitz WS, Kuwada SK, Leppert MF, Burt RW: Colorectal adenomas and cancer link to chromosome 13q22.1-13q31.3 in a large family with excess colorectal cancer. J Med Genet; 2010 Oct;47(10):692-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal adenomas and cancer link to chromosome 13q22.1-13q31.3 in a large family with excess colorectal cancer.
  • Fewer than 5% of colon cancers arise in the presence of a clear hereditary cancer condition; however, current estimates suggest that an additional 15-25% of colorectal cancers arise on the basis of unknown inherited factors.
  • AIM: To identify additional genetic factors responsible for colon cancer.
  • RESULTS: A major genetic locus segregating with colonic polyps and cancer in this kindred was identified on chromosome 13q with a non-parametric linkage score of 24 (LOD score of 2.99 and p=0.001).
  • Chromosome 13q is commonly gained and overexpressed in colon cancers and correlates with metastasis, suggesting the presence of an important cancer progression gene.
  • CONCLUSIONS: This identified region may contain a novel gene responsible for colon cancer progression in a significant proportion of sporadic cancers.